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EFFECT OF CHEMICAL POCKET DISINFECTION AS AN ADJUNCT TO 
NON-SURGICAL MAINTENANCE THERAPY OF INFLAMED PERIODONTAL POCKETS 
Chad M. Riggs, D.D.S., M.S. 
University of Nebraska, 2015 
Advisor: Wayne B. Kaldahl, D.D.S. 
Purpose: Scaling and root planing with adjunctive chemical pocket disinfection (SRP+C) utilizing 
sodium hypochlorite solution has been used to treat inflamed pockets of periodontal 
maintenance patients for many years, without evidence of its benefits. The primary objective 
was to determine if SRP+C is more effective than scaling and root planing alone (SRP) in 
improving clinical outcomes. The secondary objective was to compare the effect of SRP+C and 
SRP on pro-inflammatory IL-1β, anti-inflammatory IL-1ra, and anti-inflammatory index (IL-1ra/IL-
1β ratio) found in gingival crevicular fluid (GCF). 
Materials and Methods: Pockets (≥ 5 mm and BOP) of 31 maintenance patients were included. 
Test (SRP+C; 41 sites) and control (SRP; 43 sites) therapies were randomly administered. Clinical 
measurements and GCF samples were collected at baseline and 3-months post-therapy. 
Cytokine levels were determined and all data analyzed. 
Results: Both SRP+C and SRP resulted in significant improvements of all clinical outcomes with 
no differences between therapies. There were no differences between therapies in IL-1β and 
anti-inflammatory index. IL-1ra was greater in SRP+C than SRP post-therapy (P = 0.007). When 
the results of both therapies were combined, the anti-inflammatory index was greater (P = 0.02) 
with a trend in greater PD reduction (P = 0.0552) in sites where bleeding on probing (BOP) 
resolved compared to unresolved sites.  
Conclusions: The addition of sodium hypochlorite to scaling and root planing did not improve 
clinical parameters in inflamed pockets of periodontal maintenance patients, but increased anti-
inflammatory IL-1ra. 
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INTRODUCTION 
 Chronic periodontitis is an inflammatory disease affecting the attachment apparatus 
supporting the teeth (AAP Parameters of Care 2000). This apparatus is termed the periodontium 
and includes the gingiva, periodontal ligament, cementum, and alveolar bone. According to the 
Center for Disease Control and Prevention in 2012, approximately half of adults aged 30 or over 
have some form of periodontal disease (Eke et al. 2015) and its prevalence and severity 
increases with age (Lindhe et al. 1999).  
 Periodontal disease may clinically manifest as gingival erythema, pain, increased gingival 
crevicular fluid (GCF), tooth mobility, bleeding on probing (BOP), clinical attachment level (CAL) 
loss, increased probing depth (PD), suppuration, and gingival recession (REC). If left untreated, 
the tooth-supporting bone and gingival tissue may progressively break down and result in tooth 
loss (AAP Position Paper 1999). 
  Diagnosis of chronic periodontitis is made based on the observation of traditional 
clinical parameters such as: presence or absence of signs of inflammation, severity of 
attachment loss and bone destruction, pocketing, extent and pattern of involved teeth, medical 
and dental histories, pain, ulceration, and amount of plaque and calculus present (AAP Position 
Paper 2003). Chronic periodontitis must be differentiated from other diagnoses similar in clinical 
presentation such as aggressive periodontitis or periodontitis as a manifestation of systematic 
disease (Armitage 1999). These other diseases possess different etiologies and pathogeneses. 
Accurate diagnosis allows formation of an appropriate treatment plan. 
 The presence of bacteria is widely accepted to be the etiology of chronic periodontitis. 
Although over 500 species of microorganisms have been identified in periodontal pockets, it is 
likely that only a small percentage of these are etiologic agents (Moore & Moore 1994). These 
select bacteria possess pathogenic characteristics, such as virulence factors which overwhelm or 
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subvert the host immune system, causing periodontal destruction. Additionally, host 
susceptibility plays a major role in whether or not the bacterial presence will result in the 
development of periodontitis. Genetic factors involving dysfunctional neutrophils (Van Dyke et 
al. 1985), IL-1 polymorphism (Karimbux et al. 2012), and hyper-responsive monocytes (Garrison 
& Nichols 1989) have been hypothesized to contribute to various forms of periodontitis. 
The overall clinical goals of treating chronic periodontitis are to reduce gingival 
inflammation, arrest or slow the progression of periodontal destruction, restore the lost 
periodontium when possible, and bring the patient into comfortable function. This is 
accomplished by addressing bacteria with disruption of the biofilm, reducing microbial load, and 
minimizing future recolonization. Treatment objectives aim to reduce PD, gingival inflammation 
(BOP), plaque index (PI), and gain CAL. Treatment modalities vary and may include non-surgical 
and/or surgical therapies. 
Non-surgical therapy consists of debridement of the teeth and involves scaling and root 
planing. This may include the use of hand instruments such as curettes and/or ultrasonic scalers. 
Instrumentation of the crown and root removes plaque and calculus, reduces subgingival 
bacterial load (Socransky et al. 2013), and detoxifies the roots (Nishimine & O’Leary 1979). Many 
studies have demonstrated that scaling and root planing improves the periodontal health in 
reducing PD, BOP, PI, and gaining CAL (Kaldahl et al. 1996a, Becker et al. 2001, Hung & Douglass 
2002). Scaling and root planing is considered the “gold standard” of treating periodontal disease 
(Cobb 2002). Other factors (e.g., occlusal trauma, iatrogenic restorations, tooth crowding, 
smoking) that may be contributing to the disease may also be addressed in conjunction with 
scaling and root planing. In some cases, surgical therapy is recommended and may coincide with 
or may take place after non-surgical therapy to treat non-responding sites. 
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Long-term success of treating periodontal disease is well-documented with high tooth 
survival rates, CAL stability, reduced PDs, and reduced inflammation (Kaldahl et al. 1996a, 
Becker et al. 2001, Hung & Douglass 2002). Following active therapy (non-surgical or surgical), 
participation in periodontal maintenance is critical to long-term success (Nyman et al. 1975, 
Nyman et al. 1977, Becker et al. 1984a, Becker et al. 1984b, Wilson et al. 1987). The purpose of 
maintenance therapy is to disturb the subgingival bacteria and reduce the microbial load 
(Listgarten et al. 1978, Magnusson et al. 1984, Oosterwaal et al. 1987). This involves frequent 
visits (usually every 3-4 months) where the condition of the periodontium is measured and 
evaluated. Daily plaque control is reviewed and reinforced. Residual pockets demonstrating 
clinical inflammation (i.e., BOP) is indicative of histologic inflammation (Amato et al. 1986) and 
presence of subgingival bacteria (Wilson et al. 2008). Treatment with additional scaling and root 
planing is usually prescribed and is effective (Kaldahl et al. 1996b). Patients that receive active 
therapy and decline maintenance care usually regress back to an active diseased state (Axelsson 
& Lindhe 1981, Becker et al. 1984a, Becker et al. 1984b). 
 However, not all patients or sites respond well to conventional periodontal therapies. 
Reduction in bacteria after instrumentation is not always sufficient for an adequate host 
response (Slots et al. 1979). Consequently, adjunct therapies to scaling and root planing have 
been employed such as systemic antibiotics (Sgolastra et al. 2012, Garcia Canas et al. 2015), 
local delivery of antibiotics (Bonito et al. 2005), subgingival irrigation (Shiloah & Hovious 1993), 
and lasers (Cobb 2006) with mixed results. The purpose of adjunctive therapies is to further 
decrease the subgingival microbiota so the immune system is able to elicit a sufficient healing 
response. Chemical pocket disinfection is one such adjunctive therapy that has long been used 
without any evidence of its efficacy in the inflamed pockets of maintenance patients (Kalkwarf 
et al. 1982).    
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LITERATURE REVIEW: CHEMICAL POCKET DISINFECTION/CHEMICAL CURETTAGE 
 
History and findings: 
The development of chemical pocket disinfection originated with the procedure called 
“gingival curettage.” The stated objective of curettage is to remove the sulcular epithelium and 
any chronically inflamed tissues in the pocket walls, which would theoretically promote pocket 
shrinkage and new junctional epithelium or connective tissue attachment to the tooth.  
Curettage is accomplished by using mechanical instruments, such as a curette 
(Hirschfeld 1952) or ultrasonic curette (Goldman 1960, Nadler 1962), along the pocket wall and 
is oftentimes performed in conjunction with scaling and root planing. However, gingival 
curettage frequently results in incomplete removal of pocket epithelium (Stone et al. 1966, 
Waerhaug 1955, Vieira et al. 1982), with the exception of surgical removal by incision (Yukna 
1976). The use of chemical solutions, also known as “chemical curettage,” was subsequently 
investigated to address the shortcoming of incomplete epithelium removal. Various solutions 
(e.g., sodium sulfide, phenol camphor, antiformin, sodium hypochlorite) have been studied for 
this purpose (Miller & Sorrin 1927, Waerhaug & Loe 1958); however, only studies using sodium 
hypochlorite were included in this review. In early literature, the generic term “antiformin” was 
commonly used to describe various mixtures of sodium hypochlorite solutions and can be read 
interchangeably with the term “sodium hypochlorite.”  
Chemical curettage was introduced as an aid to periodontal therapy in the early 1900s 
(Hecker 1913) in which solutions (e.g., sodium hypochlorite/antiformin) removed pocket 
epithelium via tissue necrosis. In the 1950s, a group of Canadian clinicians published descriptive 
techniques using chemicals to facilitate gingival curettage therapy (Box 1952, Box 1953, Shaw 
1953). Their anecdotal findings claimed that chemical curettage therapy was safe, rapid, and 
provided predictable removal of all epithelium from the pocket. They further claimed that the 
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chemical removal of soft tissue was limited to epithelium, but later studies proved that its 
chemical action could progress further into the connective tissue (Glickman & Patur 1955, 
Hunter 1955, Johnson & Waerhaug 1956). Consequently, most clinicians stopped using this 
therapy due to its uncontrollable invasive potential. A later study by Kalkwarf et al. (1982) 
showed that with a strict protocol, the chemical action could be predictably limited and would 
heal normally. The appropriate time of chemical application was determined in this study to be 
one minute, followed by neutralization, and then debris removal with six curette strokes. 
Histological evidence of complete removal of pocket epithelium with normal healing was shown 
with this protocol.  
The immediate effect of chemical curettage consists of complete necrosis of the 
epithelium and superficial layer of connective tissues forming a necrotic layer. Greater levels of 
inflammation lead to less uniformity of chemolytic effects and tissue necrosis (Kalkwarf et al. 
1982). In a monkey study which observed histologic healing after application of sodium 
hypochlorite, the necrotic layer was mostly removed by the host’s normal inflammatory 
response after 16 hours, epithelial lining had reformed after 3 days, and nearly complete healing 
was achieved without any sign of irreparable damage after 11 days (Johnson & Waerhaug 1956). 
In a human observation of healing after sodium hypochlorite delivery, the necrotic layer was 
removed by the host’s normal inflammatory response, epithelial lining was restored after 7 
days, and ongoing fibroblastic proliferation with continued maturation of connective tissue 
fibers was observed after 14 days (Kalkwarf et al. 1982).  
Histologic studies on healing for chemical curettage are limited; therefore, the following 
comments are from studies observing mechanical curettage which will be used to describe the 
remainder of the healing considering the great similarity of therapy. Healing is initiated by the 
formation of a blood clot in the pocket immediately after curettage. Dilated blood vessels are 
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present in the tissues and numerous neutrophils migrate to the wound surface. Granulation 
tissue rapidly proliferates. Neutrophil numbers decrease after 2-5 days unless bacterial plaques 
are present and lymphocytes and plasma cells appear. Reformation and epithelialization of the 
sulcus occurs in 2 to 7 days. Junctional epithelium restoration occurs in as little as 5 days. 
Immature collagen fibers appear within 21 days with a decrease in the number of small blood 
vessels as the granulation tissue matures (Moskow 1964, Stone et al. 1966). 
Although healing after chemical and mechanical curettage therapies appear to be 
innocuous, does its healing fulfill the objective of promoting new connective tissue attachment? 
Other studies observed the histologic healing of gingival curettage and found no new connective 
tissue attachment, thus negating the main objective of removing inflamed epithelium to replace 
with connective tissue attachment. In a beagle dog study, scaling and root planing with sodium 
hypochlorite-citric acid solutions were applied to ligature-induced periodontal pockets and 
compared to scaling and root planing with mechanical soft tissue curettement. No difference in 
healing between mechanical or chemical curettage was observed, which was by long junctional 
epithelium (Vieira et al. 1982). Similar healing was seen in Rhesus monkey studies that 
employed scaling and root planing with mechanical curettage (Caton & Zander 1979, Caton et al. 
1980) and in another Rhesus monkey study with complete epithelium removal by surgical 
incisions (Yukna 1976). “Windows” of connective tissue attachment interrupting the long 
junctional epithelium was noted in one of these studies (Caton & Zander 1979). In a study 
employing subgingival plaque removal without any intentional curettage, a similar long 
junctional epithelium formed (Waerhaug 1978). It is generally accepted that curettage heals 
with a long junctional epithelium similar to healing accomplished from scaling and root planing. 
Chemical curettage has been shown to eliminate bacterial loads in pockets. A study by 
Adcock et al. (1983) showed that chemical curettage does indeed have bactericidal effects and 
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can effectively eliminate bacteria from deep periodontal pockets. Sodium hypochlorite solution 
was applied to the periodontal pockets of patients less than 18 years of age with aggressive 
periodontitis, without any scaling and root planing. The results of the study were solely 
attributed to the bactericidal effects of the solution. The findings observed a significant decrease 
in the number of gram-negative anaerobes and spirochetes that lasted for 30-90 days.  
Scaling and root planing alone has also been shown to reduce bacterial loads in pockets 
by 10- to 100-fold. Gram-negative anaerobes and spirochetes were significantly reduced and 
showed a 1-6 month duration until these microorganisms repopulated to baseline levels (Slots 
et al. 1979). One would logically deduce that a combination of scaling and root planing with 
adjunctive chemical curettage would yield improved results microbiologically and even clinically; 
however, a study by Forgas & Gound (1987) showed otherwise. Scaling and root planing alone 
was compared to scaling and root planing with adjunctive chemical curettage using sodium 
hypochlorite. The percentages of spirochetes and motile rods in subgingival plaques were 
observed. Similar reductions were observed after post-therapy accompanied by gradual returns 
to baseline levels after 12 weeks. There was no difference at any time between therapies.  
Not all patients respond to scaling and root planing with a reduction in periodontal 
pathogens. Antibiotics may be necessary to enhance the disturbance of the flora in the 
subgingival plaques of periodontal pockets. Two out of six patients in a study observing the 
microbial response to scaling and root planing resulted in an insignificant shift of flora after two 
rounds of mechanical instrumentation. Only after tetracycline was administered was a 
significant flora shift and reduction achieved (Slots et al. 1979). Chemical curettage may 
enhance the antimicrobial reduction in patients with sites not responding to conventional 
periodontal therapy and should be investigated. 
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Another benefit may be a slight improved visibility and access gained from the removal 
of pocket soft tissue resulting in improved mechanical removal of plaque, calculus, and biofilm. 
This benefit has not been studied. 
No studies had evaluated the beneficial clinical effects of chemical curettage and 
directly compared it to a control group until Forgas & Gound (1987) compared scaling and root 
planing alone to scaling and root planing with adjunctive chemical curettage using sodium 
hypochlorite and citric acid. Periodontal measures were recorded and no difference in PD 
reduction or CAL gain was found between groups leading to the conclusion that chemical 
curettage did not provide additional benefits to scaling and root planing. 
The history of curettage has been controversial. Studies on gingival or chemical 
curettage show no healing or clinical benefits in treating periodontitis. Upon review of the 
literature on gingival curettage, the American Academy of Periodontology released a statement 
in 2002 stating that gingival curettage “has no additional benefit to SRP [scaling and root 
planing] alone in the treatment of chronic periodontitis” (AAP Statement 2002). Resultantly, 
most research on sodium hypochlorite for curettage use in periodontal therapy has halted. Most 
dentists no longer use chemical curettage in initial periodontal therapy today, but some still 
implement it in their periodontal maintenance patients. No studies have evaluated its potential 
role in periodontal maintenance as a pocket disinfectant to reduce inflammation in select sites.  
Sodium hypochlorite properties and mechanism of action: 
Sodium hypochlorite has been used as a disinfectant for more than 100 years, as an 
antiseptic for more than 85 years, and as an endodontic irrigant for more than 75 years. It has 
many of the properties of an ideal antimicrobial agent due to its high pH, including broad 
antimicrobial activity, rapid bactericidal action, no color, no staining, ease of access, and very 
low cost. The active species is undissociated hypochlorous acid and is lethal to most bacteria, 
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fungi, viruses, as well as any other organic tissues. Its mechanism of action is reduced by the 
presence of organic material, heavy metal ions, and low pH (Slots 2002).  
Sodium hypochlorite inhibits key enzymatic reactions within the cell, denatures protein, 
and inactivates nucleic acids. It interacts with infectious organisms and host cells through three 
main reactions: saponification, neutralization, and chloramination. When sodium hypochlorite 
contacts fatty acids, a saponification reaction occurs yielding soap (fatty acid salt) and glycerol 
(alcohol). When it contacts amino acids, either a neutralization or chloramination reaction 
occurs yielding water and salt, or chloramine and water, respectively (Estrela et al. 2002). 
Highly concentrated sodium hypochlorite is a strong base (pH > 11).  The high pH alters 
the integrity of the cytoplasmic membrane by denaturing proteins and phospholipids of the 
membrane. It also irreversibly inhibits enzymes within the membrane. Sodium hypochlorite in 
high concentrations will more aggressively degrade microbes and organic tissue while lower 
concentrations (0.5-1%) are biocompatible (Estrela et al. 2002). Sodium hypochlorite-specific 
resistance by bacteria has yet to be reported (McDonnell & Russell 1999). 
Other Dental Uses: 
Sodium hypochlorite is primarily used in dentistry today as an endodontic irrigant and is 
commonly used at a concentration of 5.25%. It first appeared in the endodontic literature in 
1920 (Crane 1920) and is now routinely used around the world. Sodium hypochlorite is an 
effective antimicrobial and has tissue-dissolving capabilities. Its benefits include having a low 
viscosity (allowing easy introduction into the canal architecture), an acceptable shelf life, wide 
availability, and low cost. The main disadvantages in dental use are the toxicity to vital tissues 
and corrosion of metals (O’Hoy et al. 2003). It is possible to possess an allergy to sodium 
hypochlorite, although a few clinical reports indicate it is very rare (Caliskan et al. 1994). 
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Sodium hypochlorite is also used as a solution in subgingival irrigation and mouth rinse. 
In subgingival irrigation, a dilute solution of 0.5% sodium hypochlorite is expressed directly into 
the pocket during periodontal therapy with the objectives of reducing microbial load and plaque 
pH. Using diluted doses of sodium hypochlorite in subgingival irrigation, although inherently 
different from the chemical curettage protocol, has been shown to reduce plaque and gingivitis, 
as well as reduce plaque pH levels for 24 hours even with the challenge of a sugary rinse 
(Lobene et al. 1972). The American Dental Association Council on Dental Therapeutics has 
designated dilute sodium hypochlorite as a “mild antiseptics mouth rinse” and suggested its use 
for direct application to mucous membranes and wounds (ADA 1984). 
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LITERATURE REVIEW: PERIODONTITIS, INTERLEUKEN-1β, AND INTERLEUKIN-1ra 
Periodontal disease is caused by bacteria in dental plaque with evidence that specific 
bacterial pathogens are responsible for the progressive form of the disease. However, some 
individuals possess these specific microorganisms but do not appear to show evidence of 
disease progression (Haffajee et al. 2004). This implies that there are various degrees of patient 
susceptibility which may involve the host immune system. Although periodontal bacteria are the 
major etiological agents, the host immune response to these bacteria is of fundamental 
importance. 
Detecting susceptible individuals is currently difficult. There is great variability in the 
microbial composition between individuals and from site to site in the same individual. Each 
bacterium has a unique set of virulence factors and strains with various phenotypes (Griffen et 
al. 1999). Most periodontal disease is chronic; however, the nature of its chronicity is not 
entirely known with respect to the frequency and rate of disease progression. It is hypothesized 
that periodontitis is either a continuous or episodic process, or a combination of the two 
(Goodson et al. 1982, Gilthorpe et al. 2003). There are still many aspects of periodontal disease 
not yet understood. 
What is known is that there is an established relationship between periodontal 
destruction and inflammation (Van Dyke 2008). The interaction between periodontal pathogens 
and immune system results in chronic gingival inflammation; thus, leading to progressive 
destruction of nearby connective tissue attachment and alveolar bone around the teeth. In the 
acute phase of the periodontal lesion, large numbers of neutrophils migrate toward the infected 
site. In the latter phase, a dense infiltrate forms composed mainly of lymphocytes, 
macrophages, and plasma cells. As the lesion becomes more established, the loss of collagen 
and fibroblast alteration increases (Page & Schroeder 1976). Periodontal destruction is 
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dependent on the concentration of inflammatory mediators present in gingival tissue and 
penetration of these mediators within the gingival tissue to reach a critical distance from the 
alveolar bone (Graves & Cochran 2003). Page & Schroeder (1981) showed that bone resorption 
ceases when a 2.5 mm zone is created between the site of bacteria and bone. They concluded 
that the closer inflammatory cells are to the bone, the greater the amount of degradation.  
Inflammation involves both the innate and adaptive immune responses (Graves 2008). 
Leukocytes are recruited within the innate and adaptive responses and are the primary 
producers of cytokines that initiate and sustain inflammation. Cytokines are cell signaling 
molecules that aid cell-to-cell communication in immune responses. Cytokines stimulate the 
movement of cells toward sites of inflammation and infection, and influence the production and 
activation of different effector cells. A delicate balance of cytokine regulation is necessary for 
disease to be controlled.  Heightened cytokine production may result in more destructive or 
progressive disease. Further study of cytokines may shed light on the host response on why 
some individuals may be more susceptible to periodontal disease than others and how to better 
control inflammatory disease. 
It is possible to measure cytokines in GCF of diseased pockets to study inflammation 
with the use of enzyme-linked immunosorbent assay (ELISA) techniques. GCF is an inflammatory 
exudate originating from subgingival microvasculature that can be collected within the gingival 
sulcus. Although GCF originates from the vasculature, systemic cytokine levels of the blood 
serum do not accurately depict the inflammatory state in the periodontium, or vice versa, as 
most of the cytokines are released locally and not systemically in periodontal disease (Orozco et 
al. 2006, Trombelli et al. 2010). Several inflammatory markers have been identified in GCF of 
periodontally involved teeth, including interleukin-1 beta (IL-1β) (Masada et al. 1990, Preiss & 
13 
 
Meyle 1994) and interleukin-1 receptor antagonist (IL-1ra) (Kabashima et al. 1996, Ishihara et al. 
1997).  
IL-1β is a pro-inflammatory cytokine that is released upon activation of the host 
inflammatory response to bacteria (Ishihara et al. 1997, Cochran 2008). It is a glucoprotein of 17 
kDa and binds to IL-1 receptor (Dinarello 1991). IL-1β is produced predominantly by monocytes 
and macrophages (Mergenhagen 1984, Matsuki et al. 1992), and also by fibroblasts, dendritic 
cells, Langerhans cells, B cell lines, endothelial cells, neutrophils, epithelial cells, and bone cells 
(Oppenheim et al. 1986, Horowitz 1993). Its production may be induced by microorganisms, 
microbial products, inflammatory agents, and antigens (Preiss & Meyle 1994). Some of its pro-
inflammatory effects include: stimulation of T-lymphocytes and lymphokine production (Mizel 
1987), proliferation of B-lymphocytes and antibody production (Chiplunkar et al. 1986), 
fibroblast proliferation, stimulation of prostaglandin (PGE2) released by monocytes and 
fibroblasts, enhancement of neutrophil chemotaxis and activation (Sauder et al. 1984), and 
release of metalloproteinases that degrade extracellular matrix proteins (Dinarello 1991). 
Critical to the prognosis of periodontal disease, IL-1β also promotes osteoclast formation and is 
a potent inducer of bone demineralization (Dewhirst et al. 1985). IL-1β is a major mediator of 
tissue destruction in periodontal disease (Page et al. 1997).  
IL-1β can be predictably measured in GCF and has been shown to be present at an 
increased level in periodontally involved sites compared to healthy sites. A study by Preiss & 
Meyle (1994) sampled diseased sites from 19 untreated patients with moderate to severe 
periodontitis and from 14 sites in healthy control patients. All samples successfully detected IL-
1β. The diseased patients had a mean concentration of 313 ng/mL (range: 132-844) and healthy 
patients had a mean of 73 ng/mL (range: 35-141). Another study by Goutoudi et al. (2004) 
recruited 12 patients with moderate to advanced levels of periodontal disease and sampled 24 
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non-diseased sites and 72 diseased sites multiple times. IL-1β was successfully detected in 382 
out of 384 samples and the mean total amount of IL-1β was significantly higher in diseased sites 
compared to non-diseased sites at baseline. 
The amount of IL-1β in GCF is closely associated with the severity of periodontal disease 
and active inflammation. Ishihara et al. (1997) evaluated the correlation of IL-1β levels in GCF 
and the clinical status of patients with slight, moderate, or severe levels of periodontitis and 
healthy controls. No IL-1β was detected in the GCF obtained from non-inflamed sites of the 
healthy subjects. The total amount of IL-1β was correlated with alveolar bone loss. Engebretson 
et al. (2002) showed a strong correlation with IL-1β levels and both pocket depth and 
attachment levels. Conversely, Masada et al. (1990) found no correlation of IL-1 (α and β) levels 
and pocket depth. This was explained by pocket depth being only reflective of cumulative 
history of periodontal disease and does not indicate current disease activity. In a similar study, 
Mogi et al. (1999) measured IL-1β and found an association with levels of IL-1β and pocket 
depth and BOP (active inflammation). It is generally concluded that measuring the IL-1 
biomarker in GCF may be valuable in detecting the activity of inflammation and breakdown in 
periodontal tissues. 
In the initial and maintenance phase of periodontal therapy, pockets with inflammation 
(i.e., BOP) are primary targets due to the likely presence of root surface irritants (Ramfjord 1987, 
Ramfjord et al. 1987). Reinhardt et al. (2010) investigated the relationship between IL-1β and 
subsequent attachment and bone loss in postmenopausal women with moderate to advanced 
periodontitis. Maintenance patients who experienced an increase in IL-1β from the previous 
year’s visit were twice as likely to have progression of periodontitis in the following year.  
Scaling and root planing has been consistently shown to reduce clinical inflammation 
and the amount of IL-1β in periodontally diseased sites (Hou et al. 1995, Tsai et al. 1995, 
15 
 
Engebretson et al. 2002, Goutoudi et al. 2004). This reduction in IL-1β may last up to 24 weeks 
before returning to baseline levels (Engebretson et al. 2002). Smoking may have a negative 
effect on periodontal therapy as shown by Goutoudi et al. (2004). At baseline, smokers and non-
smokers had similar IL-1β levels. After therapy, smokers had significantly higher levels of IL-1β 
than non-smokers. Non-steroidal anti-inflammatory drug (NSAID) intake was not shown to 
significantly influence IL-1β in GCF (Bostrom et al. 2000, Kim et al. 2007, Buduneli et al. 2010). 
IL-1ra belongs to the IL-1 family and binds to IL-1 receptors with nearly the same avidity 
as IL-1β (Arend 2002). Its binding to IL-1 receptors does not induce a cellular response, thereby 
antagonizing the effects of IL-1β (Seckinger et al. 1987, Dinarello 2013). It is a 17-23 kDa protein 
secreted by immune cells (Roux-Lombard et al. 1989, McColl et al. 1992, Hagaman et al. 2001), 
epithelial cells (Perrier et al. 2002), keratinocytes (Gruaz-Chatellard et al. 1991), stromal cells 
(Chan et al. 1992, Kristensen et al. 1992), and adipocytes (Juge-Aubry et al. 2004). An excess of 
IL-1ra up to at least 100-fold is necessary to counteract the effects of IL-1 in vitro (Arend et al. 
1990). The function of IL-1ra is regulated only by its levels of production, since it does not induce 
signal transduction (Perrier et al. 2006).  
IL-1ra plays a defensive role in periodontitis; however, an increased secretion of IL-1ra is 
insufficient to overwhelm the release of IL-1β. Gilowski et al. (2014) showed that IL-1ra was 
significantly higher (over 1.5x greater in mean moles/sample) in the periodontitis group than in 
the control group. Holmlund et al. (2004) also showed significantly higher levels of IL-1ra in 
diseased versus control groups. Rawlinson et al. (2000) and Toker et al. (2008) showed 
contrasting results with the diseased groups having significantly lower levels of IL-1ra than the 
control group.  
Ishihara et al. (1997) showed no correlation with IL-1ra and alveolar bone loss scores 
while Toker et al. (2008) showed a negative correlation with IL-1ra and gingival index in 
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moderate pockets only. Evaluating the response to periodontal therapy, one would intuitively 
think that IL-1ra would increase to nullify the effects of IL-1β, since clinical inflammation is often 
reduced. However, Toker et al. (2008) showed that IL-1ra did not significantly change at 
diseased sites after scaling and root planing. After surgical therapy of sites with osseous defects, 
Holmlund et al. (2004) showed a non-significant decrease in IL-1ra.  
To better understand the role IL-1ra plays in periodontitis, IL-1ra cannot be studied 
alone, but rather the relationship of IL-1ra to IL-1β needs to be investigated. An imbalance 
between IL-1β and IL-1ra is one of the factors influencing the course, susceptibility, and severity 
of many diseases other than periodontitis including kidney/liver/pancreas/central nervous 
system diseases, arthritis, inflammatory bowel disease, granulomatous and fibrotic lung 
disorders, graft-versus-host disease, leukemia and cancer, osteoporosis, diabetes, infectious 
diseases, and arterial diseases (Arend 2002). Either an overproduction of IL-1β or 
underproduction of IL-1ra predisposes individuals to these diseases. The increase in circulating 
IL-1ra levels corresponds to a delayed event in response to IL-1β production and may represent 
a preventive mechanism in chronic inflammation (Opp et al. 1992). A large randomized 
controlled trial evaluated the efficacy of IL-1ra therapy in 472 patients with active and severe 
rheumatoid arthritis and found beneficial effects on the rate of joint erosion (Bresnihan et al. 
1998, Bresnihan et al. 2004). Increasing the ratio of IL-1ra/IL-1β may be therapeutic in treating 
periodontal disease. GCF concentration of IL-1ra was approximately 1000-fold that of IL-1β in 
periodontitis patients (Bostrom et al. 2000). Ishihara et al. (1997) reported that patients with 
slight alveolar bone loss had pre-therapy IL-1ra moles 600-fold that of IL-1β and severe bone 
loss patients only a 90-fold. Gilowski et al. (2014) reported GCF molar levels of IL-1ra to be 800-
fold that of IL-1β in the control group and only 300-fold in the periodontitis group, indicating a 
decrease in IL-1ra/IL-1β ratio. Further study of the IL-1ra/IL-1β ratio may be helpful in better 
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understanding the dynamics of this delicate balance of anti- and pro-inflammatory cytokines, 
and their role in periodontitis etiology and therapy. 
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MATERIALS AND METHODS 
Overview of study design: 
 Eligible patients with qualifying diseased and healthy sites were identified. An invitation 
to participate in the study was extended and consent obtained. Clinical data and GCF samples 
were collected from each study participant at sites of interest by a calibrated, blinded clinician. 
All diseased sites (test and control) received scaling and root planing by a second clinician not 
knowing which sites would receive the subsequent chemical pocket disinfection. A third clinician 
then randomly assigned which diseased sites would receive adjunctive chemical pocket 
disinfection (test) and administered this therapy. Data collection and therapies were performed 
at the same visit. Study participants returned 3-months (± 2 weeks) post-therapy for final data 
collection by the initial, blinded clinician.  
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Figure 1: Flow of study design 
  
Screening 
Informed consent 
obtained (n=33 pts) 
Baseline data collected (PI, GCF, PD, BOP, REC) by 
clinician #1 (n=33 pts) 
3-month post-therapy data collected (PI, GCF, PD, 
BOP, REC) by clinician #1 (n=31 pts; 41 SRP+C 
sites; 43 SRP sites) 
SRP therapy at all diseased 
sites by clinician #2 (n=87 
sites) 
Adjunctive chemical pocket 
disinfection randomly designated 
and administered by clinician #3 
(n=44 SRP+C sites; 43 SRP sites) 
Patient withdrawal 
(n=2 pts) 
Eligible patients 
identified, invited to 
participate (n=33 pts) 
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Patient selection: 
 The clinical phase of the study was conducted from February 2014 to November 2014. 
Patients receiving regular periodontal maintenance therapy at the University of Nebraska 
Medical Center College of Dentistry were screened by a staff dental hygienist (MC) at their 
scheduled maintenance appointment. The inclusion criteria consisted of any adult periodontal 
maintenance patient (≥ 30 years of age) with a history of therapy for chronic periodontitis, 
whose last maintenance therapy occurred within the past 3-6 months, and had one or more 
sites of ≥ 5 mm PD with BOP. Non-smokers and smokers were included in the study. Exclusion 
criteria consisted of subjects who were uncontrolled diabetics, pregnant, used NSAIDs or 
anticoagulants regularly for chronic disease/pain, used antibiotics in the previous three months, 
or required antibiotic coverage for dental treatments. Patients that met the inclusion criteria 
were invited to participate in the study. Each screened patient interested in participating in the 
study had their diseased sites and history confirmed by a trained dentist (CR). The study 
protocol was explained, questions answered, and consent obtained from all subjects. 
Maintenance therapy was performed at that time by MC, leaving the sites of interest untreated. 
The patient returned as soon as possible for clinical data collection followed by administration 
of the assigned therapy. Study participants would return in three months for post-treatment 
data collection immediately followed by resumption of their regular maintenance therapy, thus 
minimally interrupting ongoing periodontal therapy. The experimental protocol was approved 
by the University of Nebraska Medical Center Institutional Review Board (IRB# 636-13-FB) and 
registered at ClinicalTrials.gov (ID# NCT02316652). 
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Data collection: 
 Data collection was composed of two parts: clinical data and GCF collection. Clinical data 
were collected from diseased study sites (pockets ≥ 5 mm with BOP), adjacent sites, and one 
healthy (H) site (PD ≤ 4 mm with no BOP) from each patient at baseline and 3-months post-
therapy. The clinical data were collected at six sites per tooth (mesio-, mid-, and disto-facial; 
mesio-, mid-, and disto-lingual) of the study teeth and adjacent teeth. GCF collection was 
performed at the diseased study sites and one H site from each patient.  
First, supragingival plaque was scored by passing a periodontal probe tip with a single 
pass along the tooth surface at the free gingival margin. Plaque was recorded using Silness & 
Loe’s PI (see Appendix A). 
Second, GCF samples were collected. Any residual supragingival plaque was cleared 
using an explorer or curette. The site was gently dried using gauze and/or air syringe, and 
isolation established using cotton rolls. GCF was collected by placing a sterile paper absorptive 
strip (PerioPaper strips, Oraflow Inc., Smithtown, NY) into the pocket or sulcus until slight 
resistance was detected. The strip was removed after 30 seconds and immediately placed in 
sterile Eppendorf micro-test tubes which were then stored in a secure freezer kept at -80°C until 
further analysis. GCF strips contaminated with blood were discarded and collection was 
repeated.  
Third, the remaining clinical parameters including PD, relative REC, and BOP were 
measured. PD was measured as the distance from the free gingival margin to the base of the 
pocket or sulcus using a periodontal probe (UNC-15 probe, Hu-Friedy, Chicago, IL) in the deepest 
point of each site. REC was defined as the measured distance from the cemento-enamel 
junction or restorative margin to the free gingival margin at the measured location of each PD. 
The presence of BOP was scored as present or absent (+/-) within 30 seconds from the time of 
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probing. Relative CAL was calculated as the sum of the PD and REC measurements. All clinical 
measures and GCF collection were performed by one calibrated, blinded examiner (CR).  
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Treatment protocol: 
 All identified study and adjacent sites were treated with scaling and root planing by a 
single clinician (MB) not involved with clinical measurements or future random allocation of 
sites to receive subsequent chemical pocket disinfection. Scaling and root planing was 
performed utilizing hand and ultrasonic instruments until a smooth, glassy root surface was 
obtained at the discretion of the clinician (MB). No local anesthesia was utilized. 
Following instrumentation, another clinician (WK) randomly allocated which study sites 
would receive chemical pocket disinfection therapy. Randomization was decided by the flip of a 
coin at every other site in numerical order, thereby alternating therapy assignment equally. Sites 
receiving chemical therapy (test) could not be in the same quadrant as sites not receiving this 
therapy (control) to prevent any chance of communication or influence due to close proximity. 
Multiple sites in the same quadrant receiving the same therapy were acceptable.  Adjacent sites 
were also treated with chemical therapy. Plaque control was reinforced. 
 Chemical pocket disinfection therapy included cotton roll isolation of the area to be 
treated. A 6% sodium hypochlorite solution (Wagey Drug Co., Lincoln, NE) (see Appendix B) was 
inserted into the pocket using a modified Orban medicament loop (Hu-Friedy, Chicago, IL) (see 
Figure 1). After 60 seconds, a 5% neutralizing citric acid solution (Wagey Drug Co., Lincoln, NE) 
was inserted into the pocket using the medicament loop. The site was then irrigated with water 
and debris removed with a curette.  
 The sodium hypochlorite solution was verified to have a pH of 14. The sodium 
hypochlorite and citric acid solutions were stored in a cool, dark environment.  
 At the conclusion of treatment, diseased sites received either test therapy: scaling and 
root planing with adjunctive chemical pocket disinfection (SRP+C), or control therapy: scaling 
and root planing alone (SRP).  
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   Figure 2: Modified Orban medicament loop used to deliver chemical solutions
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Analysis of GCF samples: 
 GCF samples were collected at all diseased sites and one H site per patient.  Only GCF 
samples from paired, treated sites (i.e., one test and one control within each patient), plus the H 
site sample, were analyzed.  
GCF samples were analyzed for IL-1β and IL-1ra using ELISA based on a quantitative 
sandwich technique. All assay procedures were performed by individuals (CR, MS) without 
knowledge of the therapy allocation and according to the manufacturer’s protocol using human 
recombinant standards. The stored GCF samples were allowed to thaw at room temperature. 
The sample strips were eluted in 1 mL of phosphate buffer solution and gently agitated for 1 
hour. 
IL-1β: 
Two-hundred µL of each standard and reconstituted GCF sample were aliquoted in 
duplicate to wells pre-coated with monoclonal antibody specific for IL-1β (Human IL-1β/IL-1F2 
Quantikine® ELISA, R&D Systems, Minneapolis, MN). After 2 hours of incubation at room 
temperature, the wells were aspirated and washed 3 times. Two-hundred µL of human IL-1β 
conjugate were added to each well and incubated for 2 hours at room temperature. Aspiration 
and washes were again performed 3 times. Two-hundred µL of substrate solution were added to 
each well and incubated for 20 minutes at room temperature in the absence of light. Fifty µL of 
stop solution were added to each well and gently agitated until a yellow color was obtained. The 
microplate was read at a wavelength of 450 nm and corrected for optical imperfections by 
subtracting the 570 nm readings to obtain the optical density of each well. 
The IL-1β standard calibration curves were generated. The minimum detectable 
concentration was 0.878 pg/mL and the maximum detectable concentration was 262 pg/mL.  
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Each GCF sample was analyzed separately. The optical density and relative IL-1β 
concentration of each sample were estimated from the standard curve. Cytokine values lower 
than the lowest detectable level were set to the lowest detected level on the microplate’s 
standard curve (occurred in one H site). Cytokine values higher than the maximum detectable 
level were set to 262 pg/mL (occurred in 13 diseased sites).  
The IL-1β concentration of a GCF sample from each site was the average of each 
sample’s duplicate. The concentration (pg/mL) was multiplied by the volume of the sample used 
for the ELISA (x0.2 mL), then multiplied by the proportion of used sample (x5) to calculate the 
total IL-1β amount per 30-second sample. 
IL-1ra: 
Due to the high quantities and large range of IL-1ra present in GCF, dilutions of 1:10 and 
1:100 of the original eluted sample were made to fit in the standard curve. One-hundred µL of 
each standard and reconstituted GCF sample were aliquoted in duplicate to wells pre-coated 
with monoclonal antibody specific for IL-1ra (Human IL-1ra/IL-1F3 Quantikine® ELISA, R&D 
Systems, Minneapolis, MN). After 2 hours of incubation at room temperature, the wells were 
aspirated and washed 4 times. Two-hundred µL of human IL-1ra conjugate were added to each 
well and incubated for 2 hours at room temperature. Aspiration and washes were again 
performed 4 times. Two-hundred µL of substrate solution were added to each well and 
incubated for 30 minutes at room temperature in the absence of light. Fifty µL of stop solution 
were added to each well and gently agitated until a yellow color was obtained. The microplate 
was read at a wavelength of 450 nm and corrected for optical imperfections by subtracting the 
570 nm readings to obtain the optical density of each well. 
The IL-1ra standard calibration curves were generated. The minimum detectable 
concentration was 6.3 pg/mL. The maximum detectable concentration was 2,100 pg/mL.  
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Each GCF sample was analyzed separately. The optical density and relative IL-1ra 
concentration of each sample were estimated from the standard curve. No cytokine values were 
lower or higher than the minimum or maximum detectable levels. 
The IL-1ra concentration of a GCF sample from each site was the average of each 
sample’s duplicate. The IL-1ra concentration measured from the 1:10 dilution was used unless it 
was greater than the maximum detectable level. If IL-1ra levels were greater than the maximum 
detectable level in the 1:10 dilution, the values measured in the 1:100 dilution microplates were 
then utilized. When using the appropriate dilution, no cytokine values were outside the 
standard curve. A dilution factor of 10 was used in the 1:10 dilution samples and a dilution 
factor of 100 was used in the 1:100 dilution samples to calculate the appropriate IL-1ra 
concentrations. The concentration (pg/mL) was multiplied by the volume of the sample used for 
the ELISA (x0.1 mL), then multiplied by the proportion of used sample (x10) to calculate the total 
IL-1ra amount per 30-second sample. 
Anti-inflammatory index (IL-1ra/IL-1β ratio): 
 IL-1ra amounts per 30-second sample were divided by IL-1β amounts per 30-second 
sample to obtain IL-1ra/IL-1β ratios. This allowed a positive whole number for the ratio and 
could be considered an “anti-inflammatory index.” This ratio also has been used in the medical 
literature (Casini-Raggi et al. 1995, Carter et al. 2004, Richette et al. 2008). 
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Statistical analyses: 
 The ideal sample size to ensure adequate power was calculated to ensure detection of 
0.5 mm change in PD from baseline to 3-months post-treatment between therapies. It was 
determined that 42 treatment sites per group would be necessary to provide an 80% power 
with α=0.05.  
 Intra-therapy analyses were performed to identify the changes in PD, CAL, BOP, and PI 
between baseline and 3-months post-treatment within each therapy. Inter-therapy analyses 
were performed to compare the differences between therapies at baseline and 3-months post-
treatment for PD, CAL, BOP, PI, IL-1β, IL-1ra, and the anti-inflammatory index (IL-1ra/IL-1β ratio).  
Data were analyzed using a paired t-test and a mixed model with the patient as the 
random effect and therapy as the fixed effect. Chi-square and the binomial procedure analyses 
were used to evaluate BOP. Analyses with P values less than 0.05 were considered statistically 
significant. 
Upon analyses of the data, a difference that appeared to be significant was observed in 
sites where BOP resolved compared to bleeding sites that did not resolve. Further investigation 
was performed and the results were deemed significant enough to be reported. The report can 
be found in the “Outcomes based on BOP resolution” subsection (p. 33). 
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RESULTS 
Examiner calibration: 
 The data collection examiner (CR) was calibrated for intra-examiner reliability and 
reproducibility on 23 patients using 105 randomly chosen sites. PD was reproducible at ± 1 mm 
for 99.0% of the measures and CAL at 88.9%. 
Patient characteristics: 
All 33 patients that were eligible and invited to participate in the study agreed to do so. 
Two patients were unable to complete the study (6.1% dropout rate). One patient did not return 
for the 3-month post-treatment exam due to a cardiovascular accident resulting in 
hospitalization one week before the scheduled appointment. The other patient returned for the 
3-month post-treatment exam but was disqualified due to an acute back injury and subsequent 
chronic usage of NSAIDs (one of the exclusion criterion). Both reasons for patient dropout were 
not believed to be related to any dental therapy. Thirty-one patients completed the study.  
All study patients were asked at the 3-month post-therapy exam if any symptoms or 
problems were experienced. No post-operative complications were encountered or reported 
throughout the study.  
 Patient characteristics at the baseline examination are displayed in Tables 1 and 2.  
Table 1: SRP+C patient characteristics at baseline 
Total # of study patients 23 
  
Mean age (range) 64.7 years (48-79) 
  
Female (%) 
Male (%) 
12 (52.2) 
11 (47.8) 
  
Smokers (%) 5 (21.7) 
Non-smokers (%) 18 (78.3) 
  
Total # of sites 41 
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Table 2: SRP patient characteristics at baseline 
Total # of study patients 25 
  
Mean age (range) 65.0 years (48-84) 
  
Female (%) 
Male (%) 
11 (44.0) 
14 (56.0) 
  
Smokers (%) 4 (16.0) 
Non-smokers (%) 21 (84.0) 
  
Total # of sites 43 
  
 
Clinical outcomes:  
The mean baseline and post-treatment measurements of clinical parameters and 
respective changes are presented in Table 3.  
Table 3: Clinical outcomes  
Clinical 
Parameter 
Therapy N 
Baseline 
(SEM) 
Mean Change 
(SEM) 
3-mo Change 
P Value 
      
PD (mm) SRP+C 
SRP 
41 
43 
5.90 (0.14) 
5.84 (0.14) 
-0.63 (0.14) 
-0.60 (0.14) 
<0.001 
<0.001 
      
CAL (mm) SRP+C 
SRP 
41 
43 
5.08 (0.36) 
4.84 (0.35) 
0.44 (0.17) 
0.26 (0.16) 
<0.01 
NS (0.18) 
      
BOP (%)** SRP+C 
SRP 
41 
43 
100 
100 
-48.8 
-30.2 
<0.0001 
<0.0001 
      
PI SRP+C 
SRP 
41 
43 
1.56 (0.12) 
1.59 (0.12) 
0.004 (0.12) 
0.07 (0.12) 
NS (1.0) 
NS (0.52) 
      
No statistically significant difference between SRP+C and SRP for each clinical parameter 
**No SEM due to use of Chi-square analysis 
NS: Not statistically significant (P ≥ 0.05) 
 
 The mean baseline PD, CAL, BOP, and PI for SRP+C and SRP sites were not statistically 
different. The mean reductions in PD for both SRP+C and SRP were significant (P < 0.001). The 
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mean gain in CAL was significant only for SRP+C (P < 0.01). All sites initially had BOP as part of 
the inclusion criteria and the decrease in BOP for both SRP+C and SRP was significant (P < 
0.0001). The difference in changes between SRP+C and SRP in PD reduction (P = 0.88), CAL gain 
(P = 0.43), BOP reduction (P = 0.08), and PI change (P = 0.70) were not significant. 
Cytokine outcomes: 
 GCF samples from 16 patients were used. One patient’s GCF samples were discarded 
due to collection error and were not included in the results.  
Cytokine comparisons for SRP+C, SRP, and H sites are shown in Tables 4-6.  
Table 4: IL-1β levels 
Therapy N 
BASELINE 
Mean (SEM)/30-sec 
3 MO POST-THERAPY 
Mean (SEM)/30-sec 
    
SRP+C 16 148 (16) pga 102 (15) pga 
    
SRP 16 119 (16) pga 96 (15) pga 
    
H 16 20 (19) pgb 18 (17) pgb 
    
Dissimilar superscripts within each column indicate significant difference (P < 0.05) 
Table 5: IL-1ra levels 
Therapy N 
BASELINE 
Mean (SEM)/30-sec 
3 MO POST-THERAPY 
Mean (SEM)/30-sec 
    
SRP+C 16 19,703 (2,797) pga 22,207 (2,683) pga 
    
SRP 16 18,561 (2,797) pga 14,564 (2,683) pgb 
    
H 16 10,876 (3,124) pgb 9,079 (3,014) pgb 
    
Dissimilar superscripts within each column indicate significant difference (P < 0.05) 
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Table 6: Anti-inflammatory index (IL-1ra/IL-1β ratio) 
Therapy N 
BASELINE 
Mean (SEM)/30-sec 
3 MO POST-THERAPY 
Mean (SEM)/30-sec 
    
SRP+C 16 345 (207)a 290 (203)a 
    
SRP 16 284 (207)a 195 (203)a 
    
H 16 1,365 (252)b 1,477 (253)b 
    
Dissimilar superscripts within each column indicate significant difference (P < 0.05) 
 
At baseline, IL-1β was significantly less in H compared to diseased sites (P < 0.0001) and 
was not significantly different between SRP+C and SRP sites (P = 0.13). At 3-months post-
therapy, IL-1β remained significantly less in H compared to diseased sites (P ≤ 0.0001) and was 
not significantly different between SRP+C and SRP sites (P = 0.72). 
At baseline, IL-1ra was significantly less in H compared to SRP+C (P = 0.007) and SRP 
sites (P = 0.02). There was no significant difference between SRP+C and SRP sites (P = 0.68). At 3-
months post-therapy, IL-1ra remained significantly lower in H compared to SRP+C sites (P = 
0.0001); however, IL-1ra was not significantly different in H compared to SRP sites (P = 0.08). IL-
1ra was significantly greater in SRP+C than SRP sites (P = 0.007) and the mean IL-ra levels 
increased only in SRP+C sites between examinations. 
At baseline, the anti-inflammatory index was significantly higher in H compared to 
SRP+C (P = 0.001) and SRP sites (P = 0.0006). There was no significant difference between SRP+C 
and SRP sites (P = 0.81). At 3-months post-therapy, the anti-inflammatory index remained 
significantly higher in H compared to SRP+C (P = 0.0006) and SRP sites (P = 0.0002). There was 
no significant difference between SRP+C and SRP sites (P = 0.74). 
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Outcomes based on BOP resolution: 
Clinical measures and cytokine levels comparing treated, diseased sites with BOP resolution to 
non-resolution of all sites combined (i.e., test and control) are shown in Tables 7-10. 
Table 7: Clinical outcomes by BOP resolution 
Clinical 
Parameter 
BOP Post-
therapy 
N 
Baseline 
(SEM) 
Mean Change 
(SEM) 
     
PD (mm) (+) 
(-) 
 
51 
33 
 
5.84 (0.15) 
5.92 (0.18) 
-0.45 (0.14) 
-0.88 (0.17) 
 
     
CAL (mm) (+) 
(-) 
51 
33 
4.85 (0.40) 
4.97 (0.46) 
-0.20 (0.16) 
-0.58 (0.20) 
     
PI (+) 
(-) 
51 
33 
1.70 (0.11) 
1.40 (0.14) 
0.02 (0.11) 
0.07 (0.14) 
     
No statistically significant difference between BOP (+) and BOP (-) for each clinical parameter 
 
Table 8: IL-1β levels by BOP resolution 
BOP Post-
therapy 
N 
BASELINE 
Mean (SEM)/30-sec 
3 MO POST-THERAPY 
Mean (SEM)/30-sec 
    
(+) 31 148 (18) pg 113 (17) pg 
    
(-) 19 113 (21) pg 79 (19) pg 
    
No statistically significant difference between BOP (+) and BOP (-) 
 
Table 9: IL-1ra levels by BOP resolution 
BOP Post-
therapy 
N 
BASELINE 
Mean (SEM)/30-sec 
3 MO POST-THERAPY 
Mean (SEM)/30-sec 
    
(+) 31 18,986 (3,323) pg 17,875 (3,170) pg 
    
(-) 19 20,561 (3,601) pg 19,135 (3,569) pg 
    
No statistically significant difference between BOP (+) and BOP (-) 
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Table 10: Anti-inflammatory index (IL-1ra/IL-1β ratio) by BOP resolution 
BOP Post-
therapy 
N 
BASELINE 
Mean (SEM)/30-sec 
3 MO POST-THERAPY 
Mean (SEM)/30-sec 
    
(+) 31 243 (173)a 191 (49)a 
    
(-) 19 462 (180)a 330 (54)b 
    
Dissimilar superscripts within each column indicate significant difference (P < 0.05) 
 
The mean baseline PD, CAL, and PI were not significantly different in sites where BOP 
resolved or did not resolve. The differences in changes between resolved and unresolved sites in 
PD reduction (P = 0.0552), CAL gain (P = 0.14), and PI change (P = 0.79) were not significant; 
although, there was a definite trend in greater PD reduction in sites where BOP resolved. 
The mean baseline levels of IL-1β, IL-1ra, and anti-inflammatory index were not 
significantly different when comparing sites where BOP resolved or remained unresolved. The 
differences in mean post-therapy levels of IL-1β and IL-1ra remained insignificant; however, the 
post-therapy anti-inflammatory index was significantly greater in sites where BOP resolved (P = 
0.02). 
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DISCUSSION 
 This single-blinded, randomized controlled trial compared clinical and cytokine 
measurements of two therapies, SRP+C (test) and SRP (control), for bleeding pockets ≥ 5 mm in 
periodontal maintenance patients over a 3-month period. Every precaution was taken to 
eliminate any bias by compartmentalizing the various aspects of this study protocol as follows:  
blinded examiner (CR) collected all data, clinician (MB) who was blinded to chemical pocket 
disinfection assignment performed all scaling and root planing, and clinician (WK) 
randomized/performed chemical pocket disinfection therapy. All of the participants in this study 
were maintenance patients on a 3- to 4-month recall program and had previously received 
periodontal therapy. The baseline clinical and cytokine measurements for SRP+C and SRP sites 
were similar. 
The current study demonstrated that inflamed pockets treated with SRP+C or SRP 
showed PD reduction, CAL gain, and BOP reduction 3-months post-therapy in a periodontal 
maintenance population. No significant differences were shown when comparing clinical 
measurements of SRP+C to SRP. Only one other known study about sodium hypochlorite has 
also compared clinical measures of SRP+C to SRP (Forgas & Gound 1987). It investigated 
untreated patients with generalized moderate periodontitis rather than maintenance patients. 
The sample size was smaller (n=10) than the current study’s sample. Nevertheless, the results 
showed clinical improvement in all treated sites compared to untreated control sites, but no 
differences between treatments in PD, CAL, or gingival index at 2-months post-therapy. The Loe 
and Silness gingival index was used to evaluate inflammation, which is broader in its criteria 
(evaluates gingival appearance in addition to BOP) compared to only recording BOP as present 
or absent. BOP is important to assess as its presence indicates histologic inflammation 
(Greenstein et al. 1981, Amato et al. 1986) and presence of subgingival bacteria (Mombelli et al. 
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2000, Wilson et al. 2008). Ideally, the goal for each maintenance patient would be to eliminate 
BOP at all sites to reduce the risk of progressive breakdown (Chaves et al. 1990, Lang et al. 
1990). 
BOP reduction was not significantly different between SRP+C and SRP groups (-48.8% vs. 
-30.2%, respectively), but SRP+C did show a trend (P = 0.08) of reducing inflammation more 
effectively. This may be attributed to more effective bacterial reduction by the disinfective 
properties of sodium hypochlorite (Adcock et al. 1983) or improved healing of the attachment 
apparatus with elimination of inflamed pocket tissues (Kalkwarf et al. 1982). Studies have shown 
that sites with BOP correlated with higher percentages of periodontal pathogens (Armitage et 
al. 1982, Demmer et al. 2008) which sodium hypochlorite has been shown to effectively reduce 
in periodontal pockets (Adcock et al. 1983). However, a previous study has shown that SRP+C 
similarly reduces subgingival bacterial load compared to SRP (Forgas & Gound 1987). Healing 
after curettage is also similar to scaling and root planing with the formation of a long junctional 
epithelium (Waerhaug 1978, Caton & Zander 1979, Caton et al. 1980). 
The CAL data had conflicting results as the CAL change between SRP+C and SRP was not 
significantly different (P = 0.43), but when evaluating each therapy independently, the CAL 
change for SRP+C was significantly improved (P = 0.01) while SRP was not significantly improved 
(P = 0.18). This may be explained by the greater BOP resolution trend in SRP+C and less probe 
penetration into the non-inflamed attachment (Listgarten et al. 1976, Magnusson & Listgarten 
1980). If so, PD also should have reflected greater reduction in SRP+C, but was essentially 
identical to results in SRP.  
 Plaque control was poor in the recruited maintenance patients. Plaque was present at 
most treated sites at both baseline and post-therapy exams, resulting in no improvement in PI. 
This may help explain why BOP did not resolve in over half of the sites for both treatments. 
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Most of the studied sites were found in posterior, interproximal sites which have been shown to 
be difficult for patients to clean effectively (Cumming & Loe 1973, Prasad et al. 2011). Improved 
PI may have resulted in better clinical results for both groups. 
 Analysis of the baseline cytokine data showed significantly higher amounts of IL-1β and 
IL-1ra for SRP+C and SRP sites compared to H sites, as expected. This finding has been reported 
by other studies (Ishihara et al. 1997, Goutoudi et al. 2004, Holmlund et al. 2004, Gilowski et al. 
2014).  
Post-therapy, IL-1β levels in SRP+C and SRP sites showed a decreasing trend. Several 
studies have demonstrated a reduction in IL-1β that also had a reduction in clinical inflammation 
after therapy (Hou et al. 1995, Tsai et al. 1995, Engebretson et al. 2002, Goutoudi et al. 2004). 
The reduction in BOP is a clinical reflection of the decrease of IL-1β. This can also be interpreted 
as a decreased risk of further periodontal destruction based on the study by Reinhardt et al. 
(2010), who showed a higher risk of future breakdown when IL-1β  increased. In the current 
study, IL-1ra increased in SRP+C sites and decreased in SRP sites, which resulted in a significant 
difference between therapies (P = 0.007). Holmlund et al. (2004) showed a decrease in IL-1ra 
after surgical therapy in moderate to advanced periodontitis. Toker et al. (2008) showed in 
aggressive periodontitis that IL-1ra did not significantly change six weeks after therapy.  
The overall decrease in IL-1β but increase in IL-1ra in sites treated with SRP+C is 
important and may relate to the enhanced BOP reduction compared to SRP. The imbalance 
between IL-1β and IL-1ra has been evaluated in many other inflammatory diseases including 
arthritis, inflammatory bowel disease, graft-versus-host disease, osteoporosis, and diabetes 
(Arend 2002). The relationship of these opposing cytokines can be expressed by the anti-
inflammatory index (IL-1ra/IL-1β ratio). Despite the decrease in IL-1β and increase in IL-1ra for 
SRP+C sites, the anti-inflammatory index did not increase. This is because the individual index 
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values for each patient determine the average index, rather than using the average IL-1β and IL-
1ra values for all patients to determine the average index.  
To better understand how IL-1β and IL-1ra relate to clinical inflammation and BOP, the 
cytokines were evaluated relative to BOP resolution rather than by therapy. Both IL-1β and IL-
1ra were reduced in similar amounts post-therapy, regardless of BOP resolution. Evaluating the 
anti-inflammatory index, a significantly higher value in the sites where BOP resolved was 
observed compared to sites with persistent BOP post-therapy (P = 0.02). This index was still 
significantly less than the H sites, but may help explain why BOP was not present 3-months post-
therapy. 
The cytokine measures were highly variable for each patient. With the large range in 
measured values, it is difficult to understand how to effectively utilize IL-1β and IL-1ra in 
everyday practice. If cytokine analyses were to be used, a baseline for each patient would need 
to be established and sites of interest can be monitored with the hope that trends may be 
detected. Clinicians may be able to predict risk of further breakdown or predictability of 
favorable pocket resolution. Further research is needed to explore how the detection of 
cytokines in GCF can be implemented in practice to enhance the treatment of periodontitis; 
however, it may be found to be unsuitable for use in clinical practice. 
The use of SRP+C in practice to treat inflamed pockets in maintenance patients is safe 
and should be considered. The adjunctive application of sodium hypochlorite utilizing a strict 
protocol ensures safe outcomes and does not cause any harm to the patient, as shown in the 
current study and in the Forgas & Gound study (1987) with similar clinical outcomes. 
Histologically, application of sodium hypochlorite in a pocket/sulcus results in normal healing 
(Johnson & Waerhaug 1956, Kalkwarf et al. 1982). The potential benefit of enhanced 
inflammation reduction may outweigh the minimal risks that it poses. 
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SRP+C may be comparable to other adjunctive therapies in its benefits and limitations. 
Currently, the most-studied adjunctive therapies commonly being used are minocycline 
(Williams et al. 2001), doxycycline (Bogren et al. 2008), chlorhexidine chips (Jeffcoat et al. 1998), 
povidone-iodine (Hoang et al. 2003), and lasers (Schwarz et al. 2008). The purpose of these 
therapies is to reduce subgingival bacterial flora and clinical signs of periodontitis. The American 
Academy of Periodontology addressed the limitations of adjunctive therapies and stated that 
local adjuncts resulted in modest improvements (PD reduction of 0.25-0.5 mm) in the clinical 
outcomes of pockets ≥ 5 mm. The AAP also stated that the use of adjuncts is not proven to 
“reduce the need for surgery or improve long-term tooth retention”, or to be cost effective (AAP 
Statement 2006). Many adjunctive therapies utilize locally-delivered antibiotics. The medical 
community is calling for more judicious antibiotic use because of the potential for promoting 
resistant bacteria and creating a “superbug” (Laxminarayan et al. 2013). Povidone-iodine and 
lasers potentially avoid the pitfalls of antibiotics; however, the benefits of povidone-iodine 
(Hoang et al. 2003, Kruck et al. 2012) and lasers (Schwarz et al. 2008, Sgolastra et al. 2013, Slot 
et al. 2014) are either limited or unproven. Sodium hypochlorite also does not have the risk of 
developing bacterial resistance (McDonnell & Russell 1999) and would provide another tool in 
the armamentarium of clinicians. Due to its limitations, adjuncts should be considered by 
clinicians only for localized recurrent and/or residual inflamed pockets ≥ 5 mm after 
conventional scaling and root planing (AAP Statement 2006). Fortunately, the incidence of 
recurrent periodontitis is very infrequent and is usually controllable with scaling and root 
planing alone (Kaldahl et al. 1996b). Further studies should be undertaken to compare SRP+C to 
other adjunctive forms of therapy. 
When analyzing the data based upon whether or not BOP resolved and ignoring the 
type of therapy given, some interesting findings were discovered. No matter the resolution of 
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BOP, both groups had improvements in PD reduction and CAL gain. Interestingly, plaque was 
present in a majority of the study sites, including sites where BOP resolved. It was expected that 
plaque would play a more influential role in the healing of inflamed pockets. Although not 
statistically significant, there was a trend for PD reduction to be greater when BOP resolved 
compared to BOP not resolving (P = 0.0552). CAL gain did not have as strong a trend (P = 0.14), 
but was still greater in sites where BOP resolved. The greater PD reduction and CAL gain can be 
expected in sites where BOP resolved due to less probe penetration into less inflamed 
attachment tissues (Listgarten et al. 1976, Magnusson & Listgarten 1980). These greater clinical 
improvements may also be a clinical manifestation of the significantly greater anti-inflammatory 
index. 
This study has several limitations. Patients were observed for only a period of three 
months and a longer duration would be ideal. Also, only two inflammatory cytokines were 
observed. IL-1β was selected due to the large number of published periodontitis studies on its 
pro-inflammatory effects and proven role in inflammation. IL-1ra was utilized due to its direct 
antagonizing effects on IL-1β. Literature on IL-1ra in periodontitis-related studies is limited. 
Numerous other cytokines are involved in the inflammatory process and IL-1β and IL-1ra only 
represent a fraction of all that is occurring in an inflamed pocket. The etiology of periodontal 
disease is initiated by bacteria and was not evaluated in this study. Also, the history of each 
study site was not investigated. Although all sites were inflamed, some may have been 
experiencing active attachment loss while others may have been periodontally stable, which 
may influence the response and inflammatory condition of the pockets. 
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CONCLUSIONS 
 SRP+C does not enhance the clinical benefits of scaling and root planing in the 
treatment of periodontal maintenance patients with inflamed pockets. However, the adjunctive 
application of concentrated sodium hypochlorite may have a positive effect on the inflammatory 
condition of the pocket. Future studies of SRP+C with larger samples and longer observation 
periods are needed to further assess the anti-microbial and anti-inflammatory effects. 
Additionally, further studies comparing SRP+C to other adjunctive therapies, such as locally-
delivered antibiotics and lasers, should be pursued. 
  
42 
 
BIBLIOGRAPHY 
Adcock JE, Berry WC Jr, Kalkwarf KL. Effect of sodium hypochlorite solution on the subgingival 
microflora of juvenile periodontitis lesions. Pediatric Dent 1983;5(3):190-194. 
Amato R, Caton J, Polson A, Espeland M. Interproximal gingival inflammation related to the 
conversion of a bleeding to a nonbleeding state. J Periodontol 1986;57(2):63-68. 
American Academy of Periodontology. The pathogenesis of periodontal diseases (position 
paper). J Periodontol 1999;70(4):457-470.  
American Academy of Periodontology. Parameter on chronic periodontitis with slight to 
moderate loss of periodontal support. J Periodontol 2000;71(Suppl. 5):853-855. 
American Academy of Periodontology. The American Academy of Periodontology statement 
regarding gingival curettage. J Periodontol 2002;73(10):1229-1230. 
American Academy of Periodontology. Diagnosis of periodontal diseases (position paper). J 
Periodontol 2003;74(8):1237-1247. 
American Academy of Periodontology. American Academy of Periodontology statement on local 
delivery of sustained or controlled release antimicrobials as adjunctive therapy in the treatment 
of periodontitis. J Periodontol 2006;77(8):1458-1458. 
American Dental Association. Accepted Dental Therapeutics. Chicago American Dental 
Association, 1984;326. 
Arend WP, Welgus HG, Thompson RC, Eisenberg SP. Biological properties of recombinant human 
monocyte-derived interleukin 1 receptor antagonist. J Clin Invest 1990;85(5):1694-1697. 
Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev 
2002;13(4-5):323-340. 
Armitage GC, Dickinson WR, Jenderseck RS, Levine SM, Chambers DW. Relationship between the 
percentage of subgingival spirochetes and the severity of periodontal disease. J Periodontol 
1982;53(9):550-556. 
Armitage GC. Development of a classification system for periodontal diseases and conditions. 
Ann Periodontol 1999;4(1):1-6. 
Axelsson P, Lindhe J. The significance of maintenance care in the treatment of periodontal 
disease. J Clin Periodontol 1981;8(4):281-294. 
Becker W, Becker BE, Berg LE. Periodontal treatment without maintenance. A retrospective 
study in 44 patients. J Periodontol 1984a;55(9):505-509. 
43 
 
Becker W, Berg L, Becker BE. The long term evaluation of periodontal treatment and 
maintenance in 95 patients. Int J Perio Rest Dent 1984b;4(2):54-71. 
Becker W, Becker BE, Caffesse R, Kerry G, Ochsenbein C, Morrison E, Prichard J. A longitudinal 
study comparing scaling, osseous surgery, and modified Widman procedures: results after 5 
years. J Periodontol 2001;72(12):1675-1684. 
Bogren A, Teles RP, Torresyap G, Haffajee AD, Socransky SS, Wennstrom JL. Locally delivered 
doxycycline during supportive periodontal therapy: a 3-year study. J Periodontol 
2008;79(5):827-835. 
Bonito AJ, Lux L, Lohr KN. Impact of local adjuncts to scaling and root planing in periodontal 
disease therapy: a systematic review. J Periodontol 2005;76(8):1227-1236. 
Bostrom L, Linder LE, Bergstrom J. Smoking and GCF levels of IL-1 beta and IL-1ra in periodontal 
disease. J Clin Periodontol 2000;27(4):250-255. 
Box KF. Periodontal disease and treatment. J Ont Dental Assoc, 1952;29:194-199. 
Box KF. Further report on antiformin. J Ont Dental Assoc, 1953;30:84-92. 
Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, Nuki G, Pavelka K, Rau 
R, Rozman B, Watt I, Williams B, Aitchison R, McCabe D, Musikic P. Treatment of rheumatoid 
arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 
1998;41(12):2196-2204. 
Bresnihan B, Newmark R, Robbins S, Genant HK. Effects of anakinra monotherapy on joint 
damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-
controlled trial. J Rheumatol 2004;31(6):1103-1111. 
Buduneli N, Buduneli E, Cetin EO, Kirilmaz L, Kutukculer N. Clinical findings and gingival 
crevicular fluid prostaglandin E2 and interleukin-1-beta levels following initial periodontal 
treatment and short-term meloxicam administration. Expert Opin Pharmacother 
2010;11(11):1805-1812. 
Caliskan MK, Turkun M, Alper S. Allergy to sodium hypochlorite during root canal therapy: a case 
report. Int Endod J 1994;27(3):163-167. 
Carter MJ, Jones S, Camp NJ, Cox A, Mee J, Warren B, Duff GW, Lobo AJ, di Giovine FS. 
Functional correlates of the interleukin-1 receptor antagonist gene polymorphism in the colonic 
mucosa in ulcerative colitis. Genes Immun 2004;5(1):8-15. 
Casini-Raggi V, Kam L, Chong YJ, Fiocchi C, Pizarro TT, Cominelli F. Mucosal imbalance of IL-1 and 
IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal 
inflammation. J Immunol 1995;154(5):2434-40. 
44 
 
Caton JG, Zander HA. The attachment between tooth and gingival tissues after periodic root 
planing and soft tissue curettage. J Periodontol 1979;50(9):462-466. 
Caton J, Nyman S, Zander H. Histometric evaluation of periodontal surgery. II. Connective tissue 
attachment levels after four regenerative procedures. J Clin Periodontol 1980;7(3):224-231. 
Chan LS, Hammerberg C, Kang K, Sabb P, Tavakkol A, Cooper KD. Human dermal fibroblast 
interleukin-1 receptor antagonist (IL-1ra) and interleukin-1 beta (IL-1 beta) mRNA and protein 
are co-stimulated by phorbol ester: implication for a homeostatic mechanism. J Invest Dermatol 
1992;99(3):315-322. 
Chaves ES, Caffesse RG, Morrison EC, Stults DL. Diagnostic discrimination of bleeding on probing 
during maintenance periodontal therapy. Am J Dent 1990;3(4):167-170. 
Chiplunkar S, Langhorne J, Kaufmann SHE. Stimulation of B cell growth and differentiation by 
murine recombinant interleukin-1. J Immunol 1986;137(12):3748-3752. 
Cobb CM. Clinical significance of non-surgical periodontal therapy: an evidence-based 
perspective of scaling and root planing. J Clin Periodontol 2002;29 Suppl 2:6-16. 
Cobb CM. Lasers in Periodontics: a review of the literature. J Periodontol 2006;77(4):545-564. 
Cochran DL. Inflammation and bone loss in periodontal disease. J Periodontol 2008;79(8 
Suppl):1569-1576. 
Crane AB. A practicable root canal technique. Philadelphia: Lea & Febinger, 1920. 
Cumming BR, Loe H. Consistency of plaque distribution in individuals without special home care 
instruction. J Periodontol Res 1973;8(2):94-100. 
Demmer RT, Papapanou PN, Jacobs DR Jr, Desvarieux M. Bleeding on probing differentially 
relates to bacterial profiles: the oral infections and vascular disease epidemiology study. J Clin 
Periodontol 2008;35(6):479-486. 
Dewhirst FE, Stashenko PP, Mole JE, Tsurumachi T. Purification and partial sequence of human 
osteoclast-activating factor: identity with interleukin 1 beta. J Immunol 1985;135(4):2562-2568. 
Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991;77(8):1627-1652. 
 
Dinarello CA. Overview of the interleukin-1 family of ligands and receptors. Semin Immunol 
2013;25(6):389-393. 
Eke PI, Dye BA, Wei L, Slade GD, Thornton-Evans GO, Borgnakke WS, Taylor GW, Page RC, Beck 
JD, Genco RJ. Update on prevalence of periodontitis in adults in the United States: NHANES 2009 
to 2012. J Periodontol 2015;86(5):611-622. 
45 
 
Engebretson SP, Grbic JT, Singer R, Lamster IB. GCF IL-1β profiles in periodontal disease. J Clin 
Periodontol 2002;29(1):48-53. 
Estrela C, Estrela CRA, Barbin EL, Spano JCE, Marchesan MA, Pecora JD. Mechanism of action of 
sodium hypochlorite. Braz Dent J 2002;13(2):113-117. 
Forgas LB, Gound S. The effects of antiformin-citric acid chemical curettage on the microbial 
flora of the periodontal pocket. J Periodontol 1987;58(3):153-158. 
Garcia Canas P, Khouly I, Sanz J, Loomer PM. Effectiveness of systemic antimicrobial therapy in 
combination with scaling and root planing in the treatment of periodontitis: a systematic review. 
J Am Dent Assoc 2015;146(3):150-163. 
Garrison SW, Nichols FG. LPS-elicited secretory responses in monocytes: Altered release of PGE2 
but not IL-1 beta in patients with adult periodontitis. J Periodontal Res 1989;24(2):88-95. 
Gilowski L, Wiench R, Plocica I, Krzeminski TF. Amount of interleukin-1β and interleukin-1 
receptor antagonist in periodontitis and healthy patients. Arch Oral Biol 2014;59(7):729-734. 
Gilthorpe MS, Zamzuri AT, Griffiths GS, Maddick IH, Eaton KA, Johnson NW. Unification of the 
“burst” and “linear” theories of periodontal disease progression: A multilevel manifestation of 
the same phenomenon. J Dent Res 2003;82(3):200-205. 
Glickman I, Patur B. Histologic study of the effect of antiformin on the soft tissue wall of 
periodontal pockets in human beings. J Am Dent Assoc 1955;51(4):420-424. 
Goldman HM. Curettage by ultrasonic instrument. Preliminary report. Oral Surg Oral Med Oral 
Pathol 1960;13:43-53. 
Goodson JM, Tanner AC, Haffajee AD, Somberger GC, Socransky SS. Patterns of progression and 
regression of advanced destructive periodontal disease. J Clin Periodontol 1982;9(6):472-481. 
Goutoudi P, Diza E, Arvanitidou M. Effect of periodontal therapy on crevicular fluid interleukin-
1β and interleukin-10 levels in chronic periodontitis. J Dent 2004;32(7):511-520. 
Graves DT, Cochran D. The contribution of interleukin-1 and tumor necrosis factor to 
periodontal tissue destruction. J Periodontol 2003;74(3):391-401. 
Graves D. Cytokines that promote periodontal tissue destruction. J Periodontol 2008;79(8 
Suppl):1585-1591. 
Greenstein G, Caton J, Polson AM. Histologic characteristics associated with bleeding after 
probing and visual signs of inflammation. J Periodontol 1981;52(8):420-425. 
Griffen AL, Lyons SR, Becker MR, Moeschberger ML, Leys EJ. Porphyromonas gingivalis strain 
variability and periodontitis. J Clin Microbiol 1999;37(12):4028-4033. 
 
46 
 
Gruaz-Chatellard D, Baumberger C, Saurat JH, Dayer JM. Interleukin 1 receptor antagonist in 
human epidermis and cultured keratinocytes. FEBS Lett 1991;294(1-2):137-140. 
Haffajee AD, Uzel NG, Arguello EI, Torresyap G, Guerrero DM, Socransky SS. Clinical and 
microbiological changes associated with the use of combined antimicrobial therapies to treat 
“refractory” periodontitis. J Clin Periodontol 2004;31(10):869-877. 
Hagaman DD, Okayama Y, D’Ambrosio C, Prussin C, Gilfillan AM, Metcalfe DD. Secretion of 
interleukin-1 receptor antagonist from human mast cells after immunoglobulin E-mediated 
activation and after segmental antigen challenge. Am J Respir Cell Mol Biol 2001;25(6):685-691. 
Hecker F. Pyorrhea alveolaris. St. Louis, C.V. Mosby Co., 1913, p.145. 
Hirschfeld L. Subgingival curettage in periodontal treatment. J Am Dent Assoc 1952;44(3):301-
314. 
Hoang T, Jorgensen MG, Keim RG, Pattison AM, Slots J. Povidone-iodine as a periodontal pocket 
disinfectant. J Peridontal Res 2003;38(3):311-317. 
Holmlund A, Hanstrom L, Lerner UH. Bone resorbing activity and cytokine levels in gingival 
crevicular fluid before and after treatment of periodontal disease. J Clin Periodontol 
2004;31(6):475-482. 
Horowitz MC. Cytokines and estrogen in bone: anti-osteoporotic effects. Science 
1993;260(5108):626-627. 
Hou LT, Liu CM, Rossomando EF. Crevicular interleukin-1β in moderate and severe periodontitis 
patients and the effect of phase I periodontal treatment. J Clin Periodontol 1995;22(2):162-167. 
Hung HC, Douglass CW. Meta-analysis of the effect of scaling and root planing, surgical 
treatment and antibiotic therapies on periodontal probing depth and attachment loss. J Clin 
Periodontol 2002;29(11):975-986. 
Hunter HA. A study of tissues treated with antiformin-citric acid. J Canad Dent Assoc 1955;21-
344. 
Ishihara Y, Nishihara T, Kuroyanagi T, Shirozu N, Yamagishi E, Ohguchi M, Koide M, Ueda N, 
Amano K, Noguchi T. Gingival crevicular interleukin-1 and interleukin-1 receptor antagonist 
levels in periodontally healthy and diseased sites. J Periodont Res 1997;32(6):524-529. 
Jeffcoat MK, Bray KS, Ciancio SG, Dentino AR, Fine DH, Gordon JM, Gunsolley JC, Killoy WJ, 
Lowenguth RA, Magnusson NI, Offenbacher S, Palcanis KG, Proskin HM, Finkelman RD, Flashner 
M. Adjunctive use of a subgingival controlled-release chlorhexidine chip reduces probing depth 
and improves attachment level compared with scaling and root planing alone. J Periodontol 
1998;69(9):989-997. 
 
47 
 
Johnson RE, Waerhaug J. Effect of antiformin on gingival tissues. J Periodontol 1956;27:24-28. 
Juge-Aubry CE, Somm E, Chicheportiche R, Burger D, Pernin A, Cuenod-Pittet B, Quinodoz P, 
Giusti V, Dayer JM, Meier CA. Regulatory effects of interleukin (IL)-1, interferon-beta, and IL-4 on 
the production of IL-1 receptor antagonist by human adipose tissue. J Clin Endocrinol Metab 
2004;89(6):2652-2658. 
Kabashima H, Nagata K, Hashiguchi I, Toriya Y, Iijima T, Maki K, Maeda K. Interleukin-1 receptor 
antagonist and interleukin-4 in gingival crevicular fluid of patients with inflammatory 
periodontal disease. J Oral Pathol Med 1996;25(8):449-455. 
Kaldahl WB, Kalkwarf KL, Patil KD, Molvar MP, Dyer JK. Long-term evaluation of periodontal 
therapy: I. Response to 4 therapeutic modalities. J Periodontol 1996a;67(2):93-102. 
Kaldahl WB, Kalkwarf KL, Patil KD, Molvar MP, Dyer JK. Long-term evaluation of periodontal 
therapy: II. Incidence of sites breaking down. J Periodontol 1996b;67(2):103-108. 
Kalkwarf KL, Tussing GJ, Davis MJ. Histologic evaluation of gingival curettage facilitated by 
sodium hypochlorite solution. J Periodontol 1982;53(2):63-70. 
Karimbux NY, Saraiya VM, Elangovan S, Allareddy V, Kinnunen T, Kornman KS, Duff GW. 
Interleukin-1 gene polymorphisms and chronic periodontitis in adult whites: a systematic review 
and meta-analysis. J Periodontol 2012;83(11):1407-1419. 
Kim DM, Koszeghy KL, Badovinac RL, Kawai T, Hosokawa I, Howell TH, Karimbux NY. The effect of 
aspirin on gingival crevicular fluid levels of inflammatory and anti-inflammatory mediators in 
patients with gingivitis. J Periodontol 2007;78(8):1620-1626. 
Kristensen M, Deleuran B, Eedy DJ, Feldmann M, Breathnach SM, Brennan FM. Distribution of 
interleukin 1 receptor antagonist protein (IRAP), interleukin 1 receptor, and interleukin 1 alpha 
in normal and psoriatic skin. Decreased expression of IRAP in psoriatic lesional epidermis. Br J 
Dermatol 1992;127(4):305-311. 
Kruck C, Eick S, Knofler GU, Purschwitz RE, Jentsch HF. Clinical and microbiologic results 12 
months after scaling and root planing with different irrigation solutions in patients with 
moderate chronic periodontitis: a pilot randomized trial. J Periodontol 2012;83(3):312-320. 
Lang NP, Adler R, Joss A, Nyman S. Absence of bleeding on probing. An indicator of periodontal 
stability. J Clin Periodontol 1990;17(10):714-721. 
Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, Vlieghe E, Hara GL, 
Gould IM, Goossens H, Greko C, So AD, Bigdeli M, Tomson G, Woodhouse W, Ombaka E, Peralta 
AQ, Qamar FN, Mir F, Kariuki S, Bhutta ZA, Coates A, Bergstrom R, Wright GD, Brown ED, Cars O. 
Antibiotic resistance-the need for global solutions. Lancet Infect Dis 2013;13(12):1057-1098. 
48 
 
Lindhe J, Ranney R, Lamster I, Charles A, Chung CP, Flemmig T, Kinane D, Listgarten M, Loe H, 
Schoor R, Seymour G, Somerman M. Consensus Report: Chronic periodontitis. Ann Periodontol 
1999;4(1):38. 
Listgarten M, Mao R, Robinson PJ. Periodontal probing and the relationship of the probe tip to 
periodontal tissues. J Periodontol 1976;47(9):511-513. 
Listgarten MA, Lindhe J, Hellden L. Effect of tetracycline and/or scaling on human periodontal 
disease. Clinical, microbiological, and histological observations. J Clin Periodontol 1978;5(4):246-
271. 
Lobene RR, Soparkar PM, Hein JW, Quigley GA. A study of the effects of antiseptic agents and a 
pulsating irrigating device on plaque and gingivitis. J Periodontol. 1972:43(9);564-568. 
Magnusson I, Listgarten MA. Histologic evaluation of probing depth following periodontal 
treatment. J Clin Periodontol 1980;7(1):26-31. 
Magnusson I, Lindhe J, Yoneyama T, Liljenberg B. Recolonization of a subgingival microbiota 
following scaling in deep pockets. J Clin Periodontol 1984;11(3):193-207. 
Masada MP, Persson R, Kenney JS, Lee SW, Page RC, Allison AC. Measurement of interleukin-1α 
and -1β in gingival crevicular fluid: Implications for the pathogenesis of periodontal disease. J 
Periodont Res 1990;25(3):156-163. 
Matsuki Y, Yamamoto T, Hara K. Detection of inflammatory cytokine messenger RNA (mRNA)-
expressing cells in human inflamed gingival by combined in situ hybridization and 
immunohistochemistry. Immunology 1992;76(1):42-47. 
McColl SR, Paquin R, Menard C, Beaulieu AD. Human neutrophils produce high levels of the 
interleukin 1 receptor antagonist in response to granulocyte/macrophage colony-stimulating 
factor and tumor necrosis factor alpha. J Exp Med 1992;176(2):593-598. 
McDonnell G, Russell AD. Antiseptics and disinfectants: activity, action, and resistance. Clin 
Microbiol Rev 1999;12(1):147-179. 
Mergenhagen SE. Thymocyte activating factor(s) in human gingival fluids. J Dent Res 
1984;63(3):461-464. 
Miller S, Sorrin S. The action and use of sodium sulphide solution as an epithelial solvent. Dent 
Cosmos 1927;69:1113-1116. 
Mizel SB. Interleukin 1 and T-cell activation. Immunol Today 1987;8(11):330-332. 
Mogi M, Otogoto J, Ota N, Inagaki H, Minami M, Kojima K. Interleukin 1 beta, interleukin 6, beta 
2-microglobulin, and transforming growth factor-alpha in gingival crevicular fluid from human 
periodontal disease. Arch Oral Biol 1999;44(6):535-539. 
49 
 
Mombelli A, Schmid B, Rutar A, Lang NP. Persistence patterns of Porphyromonas gingivalis, 
Prevotella intermedia/nigrescens, and Actinobacillus actinomycetemcomitans after mechanical 
therapy of periodontal disease. J Periodontol 2000;71(1):14-21. 
Moore WE, Moore LV. The bacteria of periodontal diseases. Periodontol 2000 1994;5:66-77. 
Moskow BS. The response of the gingival sulcus to instrumentation: a histological investigation. J 
Periodontol 1964;35:112-126. 
Nadler H. Removal of crevicular epithelium by ultrasonic curettes. J Periodontol 1962;33:220. 
Nishimine D, O’Leary TJ. Hand instrumentation versus ultrasonics in the removal of endotoxins 
from root surfaces. J Periodontol 1979;50(7):345-349. 
Nyman S, Rosling B, Lindhe J. Effect of professional tooth cleaning on healing after periodontal 
surgery. J Clin Periodontol 1975;2(2):80-86. 
Nyman S, Lindhe J, Rosling B. Periodontal surgery in plaque-infected dentitions. J Clin 
Periodontol 1977;4(4):240-249. 
O’Hoy PY, Messer HH, Palamara JE. The effect of cleaning procedures on fracture properties and 
corrosion of NiTi files. Int Endod J 2003;36(11):724-732. 
Oosterwaal PJ, Matee MI, Mikx FH, van’t Hof MA, Renggli HH. The effect of subgingival 
debridement with hand and ultrasonic instruments on the subgingival microflora. J Clin 
Periodontol 1987;14(9):528-533. 
Opp MR, Postlethwaite AE, Seyer JM, Krueger JM. Interleukin 1 receptor antagonist blocks 
somnogenic and pyrogenic responses to an interleukin 1 fragment. Proc Natl Acad Sci USA 
1992;89(9):3726-3730. 
Oppenheim JJ, Kovacs EJ, Matsushima K, Durum SK. There is more than one interleukin 1. 
Immunology Today 1986;7(2):45-56. 
Orozco A, Gemmell E, Bickel M, Seymour GJ. Interleukin-1beta, interleukin-12 and interleukin-18 
levels in gingival fluid and serum of patients with gingivitis and periodontitis. Oral Microbiol 
Immunol 2006;21(4):256-260. 
Page RC, Schroeder HE. Pathogenesis of inflammatory periodontal disease. Lab Invest 
1976;34(3):235-249. 
Page RC, Schroeder HE. Current status of the host response in chronic marginal periodontitis. J 
Periodonol 1981;52(9):477-491. 
Page RC, Offenbacher S, Schroeder HE, Seymour GJ, Kornman KS. Advances in the pathogenesis 
of periodontitis: summary of developments, clinical implications and future directions. 
Periodontol 2000 1997;14:216-248. 
50 
 
Perrier S, Kherratia B, Deschaumes C, Ughetto S, Kemeny JL, Baudet-Pommel M, Sauvezie B. IL-
1ra and IL-1 production in human oral mucosal epithelial cells in culture: differential modulation 
by TGF-beta1 and IL-4. Clin Exp Immunol 2002;127(1):53-59. 
Perrier S, Darakhshan F, Hajduch E. IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or 
Mr Hyde? FEBS Lett 2006;580(27):6289-6294. 
Prasad KV, Sreenivasan PK, Patil S, Chhabra KG, Javali SB, DeVizio W. Removal of dental plaque 
from different regions of the mouth after 1-minute episode of mechanical oral hygiene. Am J 
Dent 2011;24(1):60-64. 
Preiss DS, Meyle J. Interleukin-1β concentration of gingival crevicular fluid. J Periodontol 
1994;65(5):423-428. 
Ramfjord SP. Maintenance care for treated periodontitis patients. J Clin Periodontol 
1987;14(8):433-437. 
Ramfjord SP, Caffesse RG, Morrison EC, Hill RW, Kerry GJ, Appleberry EA, Nissle RR, Stults DL. 4 
modalities of periodontal treatment compared over 5 years. J Clin Periodontol 1987;14(8):445-
452. 
Rawlinson A, Dalati MH, Rahman S, Walsh TF, Fairclough AL. Interleukin-1 and IL-1 receptor 
antagonist in gingival crevicular fluid. J Clin Periodontol 2000;27(10):738-743. 
Reinhardt RA, Stoner JA, Golub LM, Lee H, Nummikoski PV, Sorsa T, Payne JB. Association of 
gingival crevicular fluid biomarkers during periodontal maintenance with subsequent 
progressive periodontitis. J Periodontol 2010;81(2):251-259. 
Richette P, Francois M, Vicaut E, Fitting C, Bardin T, Corvol M, Savouret JF, Rannou F. A high 
interleukin 1 receptor antagonist/IL-1beta ratio occurs naturally in knee osteoarthritis. J 
Rheumatol 2008;35(8):1650-1654. 
Roux-Lombard P, Modoux C, Dayer JM. Production of interleukin-1 (IL-1) and a specific IL-1 
inhibitor during human monocyte-macrophage differentiation: influence of GM-CSF. Cytokine 
1989;1(1):45-51. 
Sauder DN, Mounessa NC, Katz SJ, Dinarello CA, Gallin JJ. Chemotactic cytokines: the role of 
leukocytic pyrogen and epidermal cell thymocyte-activating factor in neutrophil chemotaxis. J 
Immunol 1984;132(2):828-832. 
Schwarz F, Aoki A, Becker J, Sculean A. Laser application in non-surgical periodontal therapy: a 
systematic review. J Clin Periodontol 2008;35(8 Suppl):29-44. 
Seckinger P, Williamson K, Balavoine JF, Mach B, Mazzei G, Shaw A, Dayer JM. A urine inhibitor 
of interleukin 1 activity affects both interleukin 1 alpha and 1 beta but not tumor necrosis factor 
alpha. J Immunol 1987;139(5):1541-1545. 
51 
 
Sgolastra F, Gatto R, Petrucci A, Monaco A. Effectiveness of systemic amoxicillin/metronidazole 
as adjunctive therapy to scaling and root planing in the treatment of chronic periodontitis: a 
systematic review and meta-analysis. J Periodontol 2012;83(10):1257-1269. 
Sgolastra F, Severino M, Gatto R, Monaco A. Effectiveness of diode laser as adjunctive therapy 
to scaling root planing in the treatment of chronic periodontitis: a meta-analysis. Lasers Med Sci 
2013;28(5):1393-1402. 
Shaw C. Chemical aspects of antiformin chemosurgery. J Ont Dent Assoc 1953;30:47. 
Shiloah J, Hovious LA. The role of subgingival irrigations in the treatment of periodontitis. J 
Periodontol 1993;64(9):835-843. 
Silness J, Loe H. Periodontal disease in pregnancy. II. Correlation between oral hygiene and 
periodontal condition. Acta Odont Scand 1964;22:112-135. 
Slot DE, Jorritsma KH, Cobb CM, Van der Weijden FA. The effect of the thermal diode laser 
(wavelength 808-980 nm) in non-surgical periodontal therapy: a systematic review and meta-
analysis. J Clin Periodontol 2014;41(7):681-692. 
Slots J, Mashimo P, Levine MJ, Genco RJ. Periodontal therapy in humans. I. Microbiological and 
clinical effects of a single course of periodontal scaling and root planing, and of adjunctive 
tetracycline therapy. J Periodontol 1979;50(10):495-509. 
Slots J. Selection of antimicrobial agents in periodontal therapy. J Periodontol Res 
2002;37(5):389-398. 
Socransky SS, Haffajee AD, Teles R, Wennstrom JL, Lindhe J, Bogren A, Hasturk H, Van Dyke T, 
Wang X, Goodson JM. Effect of periodontal therapy on the subgingival microbiota over a 2-year 
monitoring period. I. Overall effect and kinetics of change. J Clin Periodontol 2013;40(8):771-
780. 
Stone S, Ramfjord SP, Waldron J. Scaling and gingival curettage: a radioautographic study. J 
Periodontol 1966;37:415. 
Toker H, Poyraz O, Eren K. Effect of periodontal treatment on IL-1beta, IL-1ra, and IL-10 levels in 
gingival crevicular fluid in patients with aggressive periodontitis. J Clin Periodontol 
2008;35(6):507-513. 
Trombelli L, Scapoli C, Carrieri A, Giovannini G, Calura G, Farina R. Interleukin-1 beta levels in 
gingival crevicular fluid and serum under naturally occurring and experimentally induced 
gingivitis. J Clin Periodontol 2010;37(8):697-704. 
Tsai CC, Ho YP, Chen CC. Levels of interleukin-1 beta and interleukin-8 in gingival crevicular fluids 
in adult periodontitis. J Periodontol 1995;66(10):852-859. 
52 
 
Van Dyke TE, Schweinebraten M, Cianciola LJ, Offenbacher S, Genco RJ. Neutrophil chemotaxis 
in families with localized juvenile periodontitis. J Periodontal Res 1985;20(5):503-514. 
Van Dyke TE. The management of inflammation in periodontal disease. J Periodontol 2008;79(8 
Suppl):1601-1608. 
Vieira EM, O’Leary TJ, Kafrawy AH. The effect of sodium hypochlorite and citric acid solution on 
healing of periodontal pockets. J Periodontol 1982;53(2):71-80. 
Waerhaug J. Microscopic demonstration of tissue reaction incident to removal of subgingival 
calculus. J Periodontol 1955;26:26. 
Waerhaug J, Loe H. Effect of phenol camphor on gingival tissues. J Periodontol 1958;29:59-66. 
Waerhaug J. Healing of the dentoepithelial junction following subgingival plaque control: I. As 
observed in human biopsy material. J Periodontol 1978;1:1-8. 
Williams RC, Paquette DW, Offenbacher S, Adams DF, Armitage GC, Bray K, Caton J, Cochran DL, 
Drisko CH, Fiorellini JP, Giannobile WV, Grossi S, Guerrero DM, Johnson GK, Lamster IB, 
Magnusson I, Oringer RJ, Persson GR, Van Dyke TE, Wolff LF, Santucci EA, Rodda BE, Lessem J. 
Treatment of periodontitis by local administration of minocycline microspheres: a controlled 
trial. J Periodontol 2001;72(11):1535-1544. 
Wilson TG Jr, Glover ME, Malik AK, Schoen JA, Dorsett D. Tooth loss in maintenance patients in a 
private periodontal practice. J Periodontol 1987;58(4):231-235. 
Wilson TG, Harrel SK, Nunn ME, Francis B, Webb K. The relationship between the presence of 
tooth-borne subgingival deposits and inflammation found with a dental endoscope. J 
Periodontol 2008;79(11):2029-2035. 
Yukna RA. A clinical and histologic study of healing following the excisional new attachment 
procedure in rhesus monkeys. J Periodontol 1976;47(12):701-709. 
 
53 
 
Appendix A: Plaque index 
 
0 = No plaque. 
 
1 = A film of plaque adhering to the free gingival margin and adjacent area of the tooth. The 
plaque may only be recognized by running a probe across the tooth surface. 
 
2 = Moderate accumulation of soft deposits within the gingival pocket, on the gingival margin 
and/or adjacent tooth surface, which can be seen by the naked eye. 
 
3 = Abundance of soft matter within the gingival pocket and/or on the gingival margin and 
adjacent tooth surface. 
 
(As described in Silness & Loe 1964)  
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Appendix B: Concentrated sodium hypochlorite formula 
 
100 mL Purex bleach (6% active chlorine) 
7.8 g sodium hydroxide 
19.0 g sodium carbonate (anhydrous) 
 
pH of approximately 14 is produced. 
 
(As described in Kalkwarf et al. 1982) 
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Appendix C: Raw clinical data for SRP+C 
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2 2ML 5 6 1 -3 2 -2 4 2 1 1 0 1 2 1 
2 31ML 5 4 -1 -2 3 -2 2 -1 1 0 -1 1 2 1 
3 13DF 5 4 -1 -3 2 -3 1 -1 1 1 0 0 1 1 
3 31ML 6 6 0 -2 4 -2 4 0 1 1 0 0 0 0 
4 14DB 5 4 -1 -1 4 -2 2 -2 1 0 -1 1 2 1 
5 14DB 7 6 -1 1 8 2 8 0 1 0 -1 2 2 0 
5 18DL 5 3 -2 0 5 1 4 -1 1 0 -1 2 2 0 
6 31ML 6 6 0 -2 4 -2 4 0 1 1 0 2 2 0 
7 24DB 6 4 -2 2 8 3 7 -1 1 1 0 0 2 2 
7 32ML 5 4 -1 -2 3 -3 1 -2 1 1 0 2 2 0 
8 20DL 5 5 0 -2 3 -2 3 0 1 1 0 3 2 -1 
8 18ML 6 6 0 -3 3 -3 3 0 1 1 0 3 2 -1 
9 12ML 7 6 -1 -2 5 -2 4 -1 1 0 -1 1 2 1 
9 14ML 5 5 0 -2 3 -2 3 0 1 1 0 2 3 1 
9 31ML 5 5 0 -2 3 -2 3 0 1 1 0 2 2 0 
10 2ML 5 6 1 3 8 4 10 2 1 1 0 2 2 0 
11 3MB 9 9 0 -3 6 -2 7 1 1 1 0 1 1 0 
13 15DL 5 4 -1 -3 2 -2 2 0 1 1 0 2 2 0 
13 19ML 7 6 -1 -4 3 -5 1 -2 1 1 0 2 1 -1 
15 4ML 8 7 -1 -3 5 -3 4 -1 1 0 -1 1 1 0 
15 2DL 6 3 -3 -1 5 1 4 -1 1 1 0 1 1 0 
16 3DL 7 6 -1 -3 4 -2 4 0 1 0 -1 1 1 0 
17 14MB 5 5 0 2 7 1 6 -1 1 0 -1 2 2 0 
17 19B 6 7 1 1 7 1 8 1 1 1 0 2 1 -1 
18 19DL 5 5 0 -2 3 -2 3 0 1 1 0 2 2 0 
20 29DL 5 5 0 -4 1 -3 2 1 1 0 -1 2 2 0 
23 4L 6 5 -1 3 9 3 8 -1 1 0 -1 0 0 0 
23 14ML 6 4 -2 -2 4 -2 2 -2 1 1 0 2 2 0 
23 30ML 6 6 0 -2 4 -2 4 0 1 0 -1 2 1 -1 
24 5ML 7 7 0 1 8 1 8 0 1 0 -1 0 0 0 
24 18L 6 6 0 5 11 4 10 -1 1 1 0 2 2 0 
26 31ML 6 5 -1 0 6 0 5 -1 1 0 -1 2 2 0 
28 2ML 6 7 1 0 6 0 7 1 1 0 -1 2 0 -2 
28 11DL 7 5 -2 2 9 3 8 -1 1 0 -1 1 2 1 
28 30DL 6 4 -2 1 7 1 5 -2 1 0 -1 2 2 0 
30 15DL 6 6 0 0 6 0 6 0 1 1 0 3 2 -1 
30 30MB 7 6 -1 0 7 0 6 -1 1 0 -1 2 3 1 
31 5ML 6 3 -3 0 6 1 4 -2 1 0 -1 2 2 0 
31 14MB 6 6 0 2 8 2 8 0 1 1 0 2 0 -2 
32 3B 5 4 -1 4 9 4 8 -1 1 0 -1 0 0 0 
32 12DL 5 5 0 -1 4 -1 4 0 1 0 -1 2 2 0 
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Appendix D: Raw clinical data for SRP 
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1 31DL 5 5 0 -2 3 -2 3 0 1 1 0 2 2 0 
3 2ML 5 4 -1 -2 3 -2 2 -1 1 0 -1 1 0 -1 
3 14DL 5 5 0 -3 2 -4 1 -1 1 1 0 1 2 1 
4 19MB 5 3 -2 -2 3 -1 2 -1 1 0 -1 0 1 1 
5 3DB 6 5 -1 2 8 2 7 -1 1 1 0 0 1 1 
5 30DL 5 5 0 -2 3 -3 2 -1 1 0 -1 1 1 0 
6 9ML 6 6 0 -3 3 -3 3 0 1 0 -1 2 1 -1 
6 19DB 6 6 0 -1 5 2 8 3 1 0 -1 2 3 1 
7 11ML 5 6 1 0 5 1 7 2 1 1 0 2 2 0 
7 18ML 6 5 -1 -2 4 -1 4 0 1 1 0 2 2 0 
8 2ML 5 4 -1 -3 2 -2 2 0 1 1 0 2 2 0 
8 13MB 6 7 1 -2 4 -2 5 1 1 1 0 2 1 -1 
9 3DL 8 8 0 -2 6 -2 6 0 1 1 0 2 2 0 
9 19DL 6 5 -1 -3 3 -3 2 -1 1 1 0 1 2 1 
9 26DB 6 4 -2 2 8 2 6 -2 1 1 0 2 2 0 
10 18MB 5 5 0 2 7 2 7 0 1 1 0 2 2 0 
12 2ML 5 4 -1 -2 3 -2 2 -1 1 0 -1 2 2 0 
13 3DL 5 5 0 -2 3 -1 4 1 1 1 0 2 2 0 
14 12MB 8 8 0 -1 7 -1 7 0 1 1 0 1 2 1 
14 15DL 6 5 -1 -2 4 -1 4 0 1 1 0 1 2 1 
14 17ML 5 4 -1 -3 2 -3 1 -1 1 1 0 2 1 -1 
16 15ML 5 5 0 -2 3 -3 2 -1 1 1 0 2 2 0 
16 30DL 5 4 -1 -2 3 1 5 2 1 1 0 1 1 0 
17 30DL 5 4 -1 2 7 2 6 -1 1 1 0 2 2 0 
19 13DL 7 7 0 -4 3 -4 3 0 1 1 0 2 2 0 
21 3ML 5 4 -1 2 7 2 6 -1 1 0 -1 1 2 1 
21 31DL 7 3 -4 -1 6 0 3 -3 1 0 -1 1 1 0 
23 2ML 5 4 -1 2 7 2 6 -1 1 1 0 1 2 1 
23 18MB 5 4 -1 0 5 1 5 0 1 1 0 3 3 0 
23 23DB 9 9 0 1 10 2 11 1 1 0 -1 2 2 0 
24 14DB 7 8 1 2 9 2 10 1 1 1 0 2 0 -2 
25 5ML 7 4 -3 -2 5 -3 1 -4 1 1 0 1 1 0 
26 4ML 6 6 0 -2 4 -2 4 0 1 0 -1 0 0 0 
26 14ML 5 5 0 -4 1 -4 1 0 1 0 -1 2 2 0 
27 3DL 5 4 -1 -1 4 0 4 0 1 1 0 2 2 0 
29 2DL 7 5 -2 -2 5 -1 4 -1 1 1 0 1 2 1 
29 15DL 5 5 0 0 5 0 5 0 1 1 0 2 3 1 
30 13DL 8 7 -1 2 10 2 9 -1 1 1 0 2 2 0 
31 2ML 6 6 0 3 9 3 9 0 1 1 0 2 1 -1 
31 15DL 7 8 1 -1 6 -1 7 1 1 1 0 2 2 0 
32 5ML 5 4 -1 -1 4 0 4 0 1 0 -1 2 1 -1 
32 18ML 5 4 -1 -1 4 -1 3 -1 1 0 -1 2 2 0 
32 31ML 6 6 0 -2 4 -1 5 1 1 1 0 2 2 0 
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Appendix E: Raw IL-1β and IL-1ra cytokine data in diseased sites treated with SRP+C 
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3 13DF 130.922 16.858 -114.064 16772.100 1901.187 -14870.913 128 113 
3 31ML 159.136 10.106 -149.030 15706.160 1966.582 -13739.578 99 195 
4 14DB 87.997 22.046 -65.951 6838.541 1476.117 -5362.424 78 67 
5 14DB 89.916 79.753 -10.163 2744.788 10350.280 7605.492 31 130 
5 18DL 69.306 25.883 -43.423 7335.546 1234.154 -6101.392 106 48 
7 24DB 185.147 262.000 76.853 861.400 41041.090 40179.690 5 157 
7 32ML 93.327 183.454 90.127 1188.377 28193.740 27005.363 13 154 
8 20DL 60.760 23.539 -37.221 18588.170 7078.401 -11509.769 306 301 
8 18ML 44.364 25.171 -19.193 18657.560 18707.860 50.300 421 743 
9 12ML 262.000 255.563 -6.437 19300.050 19155.150 -144.900 74 75 
9 14ML 262.000 182.055 -79.945 29253.320 25611.020 -3642.300 112 141 
9 31ML 262.000 262.000 0 13823.250 49252.800 35429.550 53 188 
10 2ML 147.555 48.715 -98.840 25081.240 21703.840 -3377.400 170 446 
13 15DL 189.437 144.757 -44.680 40974.870 52166.630 11191.760 216 360 
16 3DL 262.000 103.048 -158.952 64550.420 17890.720 -46659.700 246 174 
17 14MB 118.196 119.853 1.657 20535.920 13361.300 -7174.620 174 111 
23 4L 70.780 42.772 -28.008 16168.760 17614.770 1446.010 228 412 
23 14ML 246.243 123.166 -123.077 22532.340 12997.920 -9534.420 92 106 
23 30ML 145.573 26.677 -118.896 20968.620 14515.640 -6452.980 144 544 
24 5ML 4.586 50.819 46.233 19323.540 52977.700 33654.160 4214 1042 
26 31ML 67.703 70.780 3.077 14245.000 19475.320 5230.320 210 275 
30 30MB 81.352 216.376 135.024 2448.139 13882.270 11434.131 30 64 
31 5ML 262.000 75.564 -186.436 16688.350 52158.140 35469.790 64 690 
31 14MB 262.000 230.032 -31.968 18993.890 43527.160 24533.270 72 189 
32 12DL 194.568 31.112 -163.456 32235.940 13190.610 -19045.330 166 424 
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Appendix F: Raw IL-1β and IL-1ra cytokine data in diseased sites treated with SRP 
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3 2ML 15.578 4.634 -10.944 1691.922 1103.363 -588.559 109 238 
3 14DL 6.055 23.893 17.838 2025.438 4451.608 2426.170 335 186 
4 19MB 167.664 79.469 -88.195 29592.160 9330.106 -20262.054 176 117 
5 3DB 30.858 62.341 31.483 5327.907 894.098 -4433.809 173 14 
5 30DL 66.321 24.959 -41.362 5471.777 2045.057 -3426.720 83 82 
7 11ML 9.182 84.372 75.190 1449.959 1613.447 163.488 158 19 
7 18ML 98.870 22.685 -76.185 6655.434 1103.363 -5552.071 67 49 
8 2ML 178.714 68.530 -110.184 28591.080 14088.140 -14502.940 160 206 
8 13MB 168.846 44.830 -124.016 27200.390 10965.390 -16235.000 161 245 
9 3DL 43.276 197.363 154.087 9371.534 12035.220 2663.686 217 61 
9 19DL 187.261 159.832 -27.429 13132.530 15910.740 2778.210 70 100 
9 26DB 219.897 105.750 -114.147 11041.860 32564.490 21522.630 50 308 
10 18MB 179.413 146.855 -32.558 32763.160 25875.920 -6887.240 183 176 
13 3DL 262.000 147.011 -114.989 48656.790 27597.730 -21059.060 186 188 
16 15ML 125.798 121.667 -4.131 22763.420 16792.640 -5970.780 181 138 
17 30DL 158.512 138.078 -20.434 7621.595 15173.670 7552.075 48 110 
23 2ML 155.908 118.196 -37.712 15544.880 14356.440 -1188.440 100 121 
23 18MB 262.000 262.000 0 33949.350 24029.650 -9919.700 130 92 
23 23DB 64.784 147.545 82.761 19475.320 27897.710 8422.390 301 189 
24 14DB 8.847 45.928 37.081 13236.520 15014.470 1777.950 1496 327 
26 4ML 53.975 29.202 -24.773 48485.770 16871.830 -31613.940 898 578 
30 13DL 262.000 262.000 0 19965.650 18028.690 -1936.960 76 69 
31 2ML 193.314 118.483 -74.831 6723.280 18877.590 12154.310 35 159 
31 15DL 85.040 28.255 -56.785 13023.140 16235.100 3211.960 153 575 
32 5ML 34.874 42.957 8.083 13509.830 17515.980 4006.150 387 408 
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Appendix G: Raw IL-1β and IL-1ra cytokine data in healthy sites 
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3 4DF 3.212 7.263 4.051 3326.807 2221.625 -1105.182 1036 306 
4 30MB 34.838 47.630 12.792 5079.404 5576.409 497.005 146 117 
5 4DB 9.466 2.218 -7.248 1005.27 966.033 -39.237 106 436 
7 6MB 7.903 12.878 4.975 939.874 11769.360 10829.486 119 914 
8 28ML 21.908 14.681 -7.227 15224.060 8010.774 -7213.286 695 546 
9 20ML 86.091 63.557 -22.534 15876.180 12540.340 -3335.840 184 197 
10 30MB 31.154 39.546 8.392 16118.640 12597.040 -3521.600 517 319 
13 29ML 2.093 10.485 8.392 8199.768 12893.130 4693.362 3918 1230 
16 13ML 1.352 0.878 -0.474 8083.885 4454.082 -3629.803 5979 5073 
17 4MB 26.519 16.894 -9.625 13613.500 12122.310 -1491.190 513 718 
23 21ML 4.981 45.139 40.158 13910.670 11612.860 -2297.810 2793 257 
24 3MB 12.239 14.527 2.288 12987.300 17291.740 4304.440 1061 1190 
26 21ML 14.054 9.557 -4.497 23405.770 11480.190 -11925.580 1665 1201 
30 5MB 0.878 1.291 0.413 4952.915 9915.561 4962.646 5641 7681 
31 12MB 64.695 5.124 -59.571 21062.960 8301.686 -12761.274 326 1620 
32 28MB 6.865 1.919 -4.946 10222.970 3513.264 -6709.706 1489 1831 
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